Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors

JP2023550355A5Inactive Publication Date: 2024-11-21VOR BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528758
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-03
Filing Date
2021-11-12
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for producing genetically engineered hematopoietic stem cells and lymphocytes for treating hyperproliferative diseases are inefficient, as they often require multiple apheresis procedures and do not effectively utilize the full range of cells present in apheresis samples, such as peripheral blood mononuclear cells (PBMCs).

Method used

Genetically engineered lymphoid cells, such as T lymphocytes and B lymphocytes, are produced from a single apheresis sample using heterologous nucleic acids encoding chimeric antigen receptors (CARs) that target lineage-specific cell surface antigens associated with hyperproliferative diseases, allowing for the production of both hematopoietic stem cells and lymphocytes from a single donor sample.

Benefits of technology

This approach enables the efficient production of genetically engineered cells that can target hyperproliferative diseases, such as hematopoietic malignancies, by utilizing cells from apheresis samples more effectively, reducing the need for multiple procedures and enhancing treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure is directed to methods and compositions relating to genetically engineered cells that express a chimeric antigen receptor, wherein the cells are recruited lymphocytes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 63 / 113,739, filed November 13, 2020, and U.S. Provisional Patent Application No. 63 / 229,017, filed August 3, 2021, which are incorporated herein by reference in their entireties. Summary of the Invention

[0002] The present disclosure is directed, at least in part, to genetically engineered cells comprising a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, wherein the cells are lymphocyte cells (or progeny thereof) obtained from a subject after hematopoietic stem cell mobilization. In one aspect, the genetically engineered cells are mobilized lymphocyte cells or progeny of the mobilized lymphocyte cells. The present disclosure is further directed, in part, to methods of producing such genetically engineered cells and methods of administering such genetically engineered cells (or progeny thereof) to a subject in need thereof. The present disclosure is based, in part, on the discovery that genetically engineered cells (e.g., CAR-expressing cells) of the present disclosure that target a lineage-specific cell surface antigen associated with a hyperproliferative disease can be generated from an apheresis sample from a subject that has undergone hematopoietic stem cell mobilization. In some embodiments, the methods described herein allow for the production of genetically engineered lymphocytes, e.g., CAR-expressing lymphocytes, and genetically engineered hematopoietic stem cells (HSCs) from the same apheresis sample taken from a subject following hematopoietic stem cell mobilization in the subject, thus avoiding multiple apheresis procedures and creating HSCs, e.g., genetically engineered HSCs, that can be used to transplant hematopoietic stem cells into a subject, as well as lymphocytes that are genetically matched to the HSCs, e.g., genetically engineered lymphocytes that express a CAR and can be administered to the same subject undergoing hematopoietic stem cell transplantation.

[0003] Without wishing to be bound by any particular theory, hematopoietic stem cells are typically collected from an apheresis sample collected from a subject after hematopoietic stem cell mobilization. However, only a subset of cells in the apheresis sample (e.g., CD34+ cells) are hematopoietic stem cells. Such apheresis samples also contain peripheral blood mononuclear cells (PBMCs), including, for example, lymphocytes and other cells. The present disclosure is directed, in part, to the discovery that cells from an apheresis sample (e.g., PBMCs) that were not collected as hematopoietic stem cells can be used to prepare genetically engineered cells, such as lymphocytes expressing chimeric antigen receptors (CAR cells). Such genetically engineered cells (e.g., CAR cells) can be used as immunotherapies and are used to treat many diseases. Furthermore, the cells and methods of the present disclosure can provide a resource-efficient means for producing the hematopoietic stem cells and genetically engineered cells (e.g., CAR cells) of the present disclosure from a single apheresis sample from a single donor subject.

[0004] Aspects of the present disclosure provide genetically engineered cells comprising a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, wherein the cell is a lymphocyte cell, and the cell or its parent cell is obtained from a subject after hematopoietic stem cell mobilization. Aspects of the present disclosure relate to genetically engineered cells comprising a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, wherein the cell is a mobilized lymphocyte cell or a progeny thereof.

[0005] In some embodiments, the genetically engineered cells are lymphoid cells, and the cells or their parent cells are obtained from a subject after hematopoietic stem cell mobilization. In some embodiments, the cells are mobilized lymphoid cells.

[0006] In some embodiments, the genetically engineered cells or recruited lymphocytes are T lymphocytes. In some embodiments, the T lymphocytes express CD3, CD4, and / or CD8 (e.g., CD4 and CD8). In some embodiments, the T lymphocytes express PD1. In some embodiments, the T lymphocytes are alpha / beta T lymphocytes, gamma / delta T lymphocytes, naive T lymphocytes, effector T lymphocytes, memory T lymphocytes, or regulatory T lymphocytes (Tregs).

[0007] In some embodiments, the genetically engineered cells or recruited lymphocytes are B lymphocytes. In some embodiments, the genetically engineered cells or recruited lymphocytes are natural killer (NK) cells.

[0008] In some embodiments, hematopoietic stem cell mobilization comprises administering to the subject etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony-stimulating factor (G-CSF).

[0009] In some embodiments, the chimeric antigen receptor is a first-generation CAR, a second-generation CAR, or a third-generation CAR.

[0010] In some embodiments, the lineage-specific cell surface antigen is CD33, CD30, CD38, CD123, CLL-1, CD5, CD6, CD7, CD19, or BCMA.

[0011] In some embodiments, the hyperproliferative disease is a hematopoietic malignancy or a myeloid malignancy. In some embodiments, the hematopoietic malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma. In some embodiments, the leukemia is acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, or chronic lymphocytic leukemia. In some embodiments, the hematopoietic malignancy is acute myeloid leukemia, myelodysplastic syndrome, or lymphoid malignancy.

[0012] In some embodiments, the genetically engineered cells are for administration to a subject in need thereof, wherein the subject has or has been diagnosed with a hematopoietic malignancy. In some embodiments, the subject has undergone a hematopoietic stem cell transplant comprising genetically engineered stem cells that have reduced or absent expression of a lineage-specific cell surface antigen, or that express a variant form of a lineage-specific cell surface antigen that is not recognized by the CAR or is recognized at a reduced level.

[0013] In some aspects, the present disclosure provides methods comprising contacting recruited lymphocytes obtained from a first subject with a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, thereby producing engineered lymphocytes that express the CAR. In some embodiments, the method further comprises administering the engineered lymphocytes, or their progeny, to a second subject, wherein the second subject is in need thereof. In some embodiments, the second subject has or has been diagnosed with a hyperproliferative disease. In some embodiments, the first subject is different from the second subject. In some embodiments, the first subject is the same as the second subject.

[0014] In some embodiments, the subject in need of administration of the genetically engineered lymphocytes or their progeny has undergone a hematopoietic stem cell transplant comprising genetically engineered hematopoietic stem cells that have reduced or absent expression of a lineage-specific cell surface antigen, or that express a variant form of a lineage-specific cell surface antigen that is not recognized by the CAR or is recognized at a reduced level. In some embodiments, the method further comprises administering a hematopoietic stem cell transplant to the subject in need thereof after administration of the genetically engineered lymphocytes or their progeny. In some embodiments, the genetically engineered lymphocytes or their progeny are administered in combination with a hematopoietic stem cell transplant comprising the genetically engineered hematopoietic stem cells.

[0015] In some embodiments, the method further comprises contacting hematopoietic stem cells obtained from the first subject with an RNA-guided nuclease and a guide RNA, or a nucleic acid encoding the same, wherein the guide RNA targets a gene encoding a lineage-specific cell surface antigen, thereby producing engineered hematopoietic stem cells that have reduced or absent expression of the lineage-specific cell surface antigen, or that express a variant form of the lineage-specific cell surface antigen. In some embodiments, the engineered hematopoietic stem cells are not targeted by a CAR, e.g., an engineered lymphocyte CAR. In some embodiments, the method further comprises administering the engineered hematopoietic stem cells, or progeny thereof, to a subject in need thereof.

[0016] In some embodiments, the genetically engineered cells or recruited lymphocytes are T lymphocytes. In some embodiments, the T lymphocytes express CD3, CD4, and / or CD8 (e.g., CD4 and CD8). In some embodiments, the T lymphocytes express PD1. In some embodiments, the T lymphocytes are alpha / beta T lymphocytes, gamma / delta T lymphocytes, naive T lymphocytes, effector T lymphocytes, memory T lymphocytes, or regulatory T lymphocytes (Tregs).

[0017] In some embodiments, the genetically engineered cells or recruited lymphocytes are B lymphocytes. In some embodiments, the genetically engineered cells or recruited lymphocytes are natural killer (NK) cells.

[0018] In some embodiments, the lineage-specific cell surface antigen is CD33, CD30, CD38, CD123, CLL-1, CD5, CD6, CD7, CD19, or BCMA. In some embodiments, the chimeric antigen receptor is a first-generation CAR, a second-generation CAR, or a third-generation CAR.

[0019] In some embodiments, the hyperproliferative disease is a hematopoietic malignancy or a myeloid malignancy. In some embodiments, the hematopoietic malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma. In some embodiments, the leukemia is acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, or chronic lymphocytic leukemia. In some embodiments, the hematopoietic malignancy is acute myeloid leukemia, myelodysplastic syndrome, or lymphoid malignancy.

[0020] In some embodiments, the RNA-guided nuclease is a CRISPR / Cas nuclease. In some embodiments, the CRISPR / Cas nuclease is a Cas9 nuclease, an SpCas nuclease, a SaCas nuclease, or a Cpf1 nuclease. In some embodiments, the nucleic acid encoding the guide RNA and / or the RNA-guided nuclease is RNA, preferably an mRNA or an mRNA analog. In some embodiments, the guide RNA comprises one or more nucleotide residues that are chemically modified. In some embodiments, the guide RNA comprises one or more nucleotide residues comprising a 2'O-methyl moiety. In some embodiments, the guide RNA comprises one or more nucleotide residues comprising a phosphorothioate. In some embodiments, the guide RNA comprises one or more nucleotide residues comprising a thioPACE moiety.

[0021] In some aspects, the present disclosure provides a cell population comprising a plurality of genetically engineered cells disclosed herein, or produced, obtained, or obtainable by the methods described herein. In some aspects, the present disclosure provides a method comprising administering any of the cell populations described herein to a subject in need thereof. [Brief explanation of the drawings]

[0022] The accompanying drawings, which constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principles of the invention.

[0023] [Figure 1] FIG. 1 is a schematic diagram illustrating an exemplary embodiment of the production of edited hematopoietic stem cells (eHSCs) and chimeric antigen receptor (CAR)-expressing cell therapy system from a single donor. [Figure 2] FIG. 2 is a schematic diagram showing an exemplary method in which edited hematopoietic stem cells (eHSCs) and chimeric antigen receptor (CAR)-expressing T cells (CAR-T cells) are produced from a single donor and administered to a patient. [Figure 3A-E] Figures 3A-3H show plots characterizing the population of mobilized peripheral blood mononuclear cells (PBMCs, referred to as the "non-target fraction" in Figure 2). Figure 3A is a flow cytometry analysis plot showing the population of CD3+ cells (T cells). Figure 3B is a flow cytometry analysis plot showing the population of CD14+ cells (monocytes). Figure 3C is a flow cytometry analysis plot showing the population of CD56+ cells (NK cells). Figure 3D is a flow cytometry analysis plot showing the population of CD19+ cells (B cells). Figure 3E presents a chart showing the relative abundance of CD3+ cells (T cells), monocytes, NK cells, and B cells in the steady-state cell fraction (left panel) or the mobilized cell fraction (right panel). [Figure 3F-H] Figure 3F is a flow cytometry analysis plot showing further characterization of the CD3+ cell (T cell) population from Figure 3A based on expression of CCR7 (y-axis) and CD45RA (x-axis). Figure 3G is a schematic showing the identification of the cell types from Figure 3F. TCM: central memory T cells, low CD45RA, high CCR7; naive: high CD45RA, high CCR7; TEM: effector memory T cells, low CD45RA, low CCR7; TEFF: effector T cells, high CD45RA, low CCR7. Figure 3H presents a chart showing the relative abundance of T cell population steady-state cell fractions (left panel) or mobilized cell fractions (right panel). [Figure 4A-C]Figures 4A-4D show immunophenotypic characterization of mobilized and non-mobilized PBMC populations. Figure 4A: Immune cell phenotyping showing CD3+ cells, monocytes, NK cells, NKT cells, and B cells. Figure 4B: Comparison of T cell phenotypes showing CD8 and CD4 populations. Figure 4C: Comparison of T cell phenotypes showing naive T cell, T effector cell (Teff), T effector memory cell (Tem), and central memory T cell (Tcm) populations. [Figure 4D] Figure 4D: Steady-state and mobilized CD8+ and CD4+ subsets. For each cell type in Figures 4A-4C, data points correspond to steady-state (left) and mobilization (right). [Figure 5] Figure 5 shows CITEseq characterization of PBMC populations from two donors (D1 and D2). In the stacked graph in the left panel, each column corresponds to, from top to bottom, B cells, CD4+ T cells, CD8+ T cells, HSPCs, macrophages, monocytes, nature killer cells, and pDC populations. In the right panel, for each cell type, the left column refers to mobilized cells, and the right column refers to steady-state cells. [Figure 6] Figure 6 shows CITEseq characterization of T cell subpopulations from two donors (D1 and D2). In the stacked graph in the left panel, each column corresponds, from top to bottom, to CD4+ T effector cells, CD4+ T naive, CD4+ TCM, CD4+ TEM, CD8+ T effector cells, and CD8+ T naive cell populations. In the right panel, for each cell type, the left column refers to mobilized cells, and the right column corresponds to steady-state cells. [Figure 7] Figure 7 shows the characterization of T cell activation in lymphocytes obtained from mobilized and non-mobilized PBMC populations from two donors (D1 and D2). For each marker, the columns, from left to right, refer to steady-state (SS) resting, mobilized (Mob) resting, SS activated, and Mob activated. [Figure 8] FIG. 8 shows the characterization of T cell activation in lymphocytes obtained from mobilized and non-mobilized PBMC populations across a larger donor cohort. [Figure 9]Figure 9 shows the results of a cytotoxicity assay using mobilized (mob) and non-mobilized (ss) PBMC-derived cells transduced with anti-CD33 CAR. For each agent, the columns correspond, from top to bottom, to dead, apoptotic, and live cells. [Figure 10] Figure 10 shows intracellular cytokine staining (ICS) analysis of TNF-alpha (TNFa+) and IFN-gamma (IFNg+) expression in mobilized and non-mobilized PBMC-derived anti-CD33 CAR-expressing cell populations in the presence and absence of CD33-expressing target cells. For each condition, columns correspond, from left to right, to no stimulation (No Stim), PMA / I, WT MOLM13, CD33KO MOLM13, and Jurkat cells. [Figure 11] Figure 11 shows the results of LUMINEX™ analysis of TNF-alpha (TNFa) and IFN-gamma (IFNg) expression in mobilized and non-mobilized PBMC-derived anti-CD33 CAR-expressing cell populations in the presence and absence of CD33-expressing target cells. For each condition, columns correspond, from left to right, to no stimulation (No Stim), PMA / I, WT MOLM13, CD33KO MOLM13, and Jurkat cells. [Figure 12-1] Figure 12 shows the results of a cytotoxicity assay of mobilized and non-mobilized PBMC-derived anti-CD33 CAR T cells in an in vivo mouse model. [Figure 12-2] Figure 12 shows the results of a cytotoxicity assay of mobilized and non-mobilized PBMC-derived anti-CD33 CAR T cells in an in vivo mouse model. DETAILED DESCRIPTION OF THE INVENTION

[0024] Hematopoietic stem cells (HSCs) for clinical use can be obtained from donor subjects after hematopoietic stem cell mobilization via apheresis. Apheresis samples obtained from such subjects typically contain a fraction of HSCs, e.g., CD34+ HSCs (sometimes referred to as the "target fraction"), and a fraction of non-stem cells, e.g., peripheral blood mononuclear cells (PBMCs) and other cells (sometimes referred to as the "non-target fraction"). Some therapeutic approaches utilize genetically engineered HSCs, e.g., edited HSCs that lack expression of lineage-specific antigens, in combination with immunotherapy, such as lymphocytes expressing chimeric antigen receptors (CARs) that target lineage-specific antigens, to specifically eradicate cells associated with malignant disease while sparing non-malignant hematopoietic cells. See, e.g., Borot et al., Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies PNAS 2019,116(24):11978-11987, and International Patent Application PCT / US16 / 057339, published as WO2017 / 066760. In such approaches, subjects typically undergo hematopoietic cell transplantation (HCT) including genetically engineered HSCs, and after successful engraftment of the HSCs in the subject, immunotherapy, e.g., CAR-T cells, is administered to the subject.

[0025] The present disclosure is directed, in part, to the discovery that mobilized lymphocytes can be used to produce genetically engineered cells (e.g., CAR cells). In some embodiments, compositions and methods are provided for producing genetically engineered hematopoietic stem cells and genetically engineered lymphocytes, e.g., CAR cells, from the same subject, e.g., from the same blood (e.g., apheresis) sample from the subject, thus efficiently providing two distinct cell populations for therapy from a single sample from a donor subject. The present disclosure is directed, in part, to genetically engineered cells comprising a heterologous nucleic acid encoding a CAR that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, wherein the cells are mobilized lymphocytes (or progeny of mobilized lymphocytes) or lymphocytes (or progeny thereof) obtained from a subject after hematopoietic stem cell mobilization. Also included herein are methods of producing and administering such cells (e.g., genetically engineered HSCs that lack expression of a lineage-specific antigen, and genetically engineered lymphocytes that express a CAR that targets a lineage-specific antigen, e.g., obtained from a single apheresis sample from a subject after hematopoietic stem cell mobilization) to a subject in need thereof, e.g., a subject with a cancer characterized by expression of a lineage-specific antigen, wherein the lineage-specific antigen is also expressed on some non-malignant cells. The present disclosure also provides methods of producing and / or administering genetically engineered hematopoietic stem cells, wherein the genetically engineered hematopoietic stem cells are not targeted by a CAR.

[0026] definition Antibody: As used herein, the term "antibody" refers to a polypeptide containing sufficient standard immunoglobulin sequence elements to confer specific binding to a particular target antigen. As is known in the art, intact antibodies produced in nature are typically tetrameric entities of approximately 150 kD, comprising two identical heavy chain polypeptides (approximately 50 kD each) and two identical light chain polypeptides (approximately 25 kD each), which associate with each other into what is commonly referred to as a "Y-shaped" structure. Each heavy chain contains at least four domains, each approximately 110 amino acids in length: an amino-terminal variable (VH) domain (located at the tip of the Y structure), followed by three constant domains: CH1, CH2, and a carboxy-terminal CH3 domain (located at the base of the stem of the Y). A short region known as the "switch" connects the heavy chain variable and constant regions. A "hinge" connects the CH2 and CH3 domains to the rest of the antibody. In intact antibodies, two disulfide bonds in the hinge region connect the two heavy chain polypeptides to each other. Each light chain contains two domains: an amino-terminal variable (VL) domain followed by a carboxy-terminal constant (CL) domain, separated from each other by another "switch." An intact antibody tetramer contains two heavy-light chain dimers linked to each other by a single disulfide bond, and two other disulfide bonds connecting the heavy chain hinge regions to each other, thereby linking the dimers to form a tetramer.

[0027] Naturally occurring antibodies are also typically glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., three-, four-, or five-stranded sheets) packed together into a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as "complementarity-determining regions" (CDR1, CDR2, and CDR3) and four relatively invariant "framework" regions (FR1, FR2, FR3, and FR4). When a natural antibody folds, the FR regions form beta sheets that provide the structural framework for the domain, and the CDR loop regions from both the heavy and light chains are assembled in three-dimensional space to generate a single hypervariable antigen-binding site located at the tip of a Y-structure. The Fc region of a naturally occurring antibody binds to elements of the complement system and also to receptors on effector cells, including, for example, those that mediate cytotoxicity. The affinity and / or other binding attributes of the Fc region for the Fc receptor can be modulated through glycosylation or other modifications. In some embodiments, antibodies produced and / or utilized in accordance with the present invention (e.g., as components of CARs) comprise a glycosylated Fc domain, including Fc domains with modified or engineered glycosylation. In some embodiments, a polypeptide or polypeptide complex comprising a full immunoglobulin domain sequence as found in a natural antibody may be referred to and / or used as an "antibody," regardless of whether such polypeptide is produced naturally (e.g., generated by an organism in response to an antigen) or by recombinant engineering, chemical synthesis, or other artificial system or methodology. In some embodiments, an antibody is polyclonal. In some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, the antibody sequence elements are humanized, primatized, chimeric, etc., as known in the art.Furthermore, as used herein, the term "antibody" can, in appropriate embodiments (unless otherwise stated or clear from the context), refer to any of the constructs or formats known or developed in the art that utilize the structural and functional characteristics of antibodies in other representations. For example, in some embodiments, antibodies utilized in accordance with the present invention are of a format selected from, but not limited to, intact IgA, IgG, IgE, or IgM antibodies, bispecific or multispecific antibodies (e.g., Zybodies®, etc.), antibody fragments, which are used herein in the broadest sense to encompass a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and / or antibody fragments (preferably, fragments that exhibit the desired antigen-binding activity). The antibodies described herein may be immunoglobulins, heavy chain antibodies, light chain antibodies, LRR-based antibodies, or other protein scaffolds with antibody-like properties, as well as other immunological binding moieties known in the art, including, for example, Fab, Fab', Fab'2, Fab2, Fab3, F(ab')2, Fd, Fv, Feb, scFv, SMIP, single domain antibodies, single chain antibodies, diabodies, tribodies, tetrabodies, minibodies, maxibodies, tandb, DVD, BiTe, Tandb, etc., or any combination thereof. The subunit structures and three-dimensional configurations of different classes of antibodies are known in the art. In some embodiments, an antibody may lack covalent modifications (e.g., glycan attachment) that it would have if produced naturally. In some embodiments, an antibody may contain covalent modifications (e.g., glycan attachment, payload (e.g., detectable moiety, therapeutic moiety, catalytic moiety, etc.), or other pendant group (e.g., polyethylene glycol, etc.)).

[0028] Antigen-binding fragment: "Antigen-binding fragment" refers to a portion of an antibody that binds to the antigen to which the antibody binds. Antigen-binding fragments of antibodies include any natural, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Exemplary antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, single-domain antibodies, linear antibodies, single-chain antibody molecules (e.g., scFv or VHH or VH or VL domains only), and multispecific antibodies formed from antibody fragments. In some embodiments, the antigen-binding fragments of antibodies described herein are scFvs. In some embodiments, the antigen-binding fragments of antibodies described herein are VHH domains only. Similar to intact antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies may comprise at least two different variable domains, each capable of specifically binding to a distinct antigen or a different epitope of the same antigen.

[0029] Antibody heavy chain: As used herein, the term "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring configuration.

[0030] Antibody light chain: As used herein, the term "antibody light chain" refers to the smaller of the two polypeptide chains present in all antibody molecules in their naturally occurring configuration.

[0031] Synthetic antibody: As used herein, the term "synthetic antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage as described herein. The term should also be taken to mean an antibody produced by synthesis of a DNA molecule encoding the antibody, where the DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence was obtained using synthetic DNA or amino acid sequence techniques available and well known in the art.

[0032] Antigen: As used herein, the term "antigen" or "Ag" refers to a molecule capable of eliciting an immune response. This immune response may involve antibody production, activation of specific immunocompetent cells, or both. Those skilled in the art will understand that virtually any macromolecule, including any protein or peptide, can function as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will understand that any DNA containing a nucleotide sequence or partial nucleotide sequence encoding a protein that elicits an immune response encodes an "antigen," as that term is used herein. Furthermore, those skilled in the art will understand that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. The present invention includes, but is not limited to, the use of partial nucleotide sequences of multiple genes, and it will be readily apparent that these nucleotide sequences can be arranged in various combinations to elicit a desired immune response. Furthermore, those skilled in the art will understand that an antigen need not be encoded by a "gene" at all. It will be readily apparent that an antigen can be synthetically produced or derived from a biological sample. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells, or biological fluids.

[0033] Autologous: As used herein, the term "autologous" refers to any material derived from an individual that is later reintroduced into the same individual.

[0034] Allogeneic: As used herein, the term "allogeneic" refers to any material (e.g., a cell population) derived from a different animal of the same species.

[0035] Hyperproliferative disease: As used herein, the term "hyperproliferative disease" refers to a disease characterized by the rapid and uncontrolled growth of abnormal cells. Hyperproliferative diseases can be benign or malignant. Malignant diseases are typically characterized by the presence of malignant cells, such as cancer cells. Cancer cells can spread locally or via the bloodstream and lymphatic system to other parts of the body. Examples of various cancers include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and the like. In certain embodiments, the hyperproliferative disease is a hematopoietic malignancy, such as a myeloid or lymphoid malignancy. In some embodiments, the hematopoietic malignancy is acute myeloid leukemia. In some embodiments, the hematopoietic malignancy is a myelodysplastic syndrome.

[0036] Conservative sequence modifications: As used herein, the term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into antibodies compatible with various embodiments by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR regions of an antibody can be substituted with other amino acid residues from the same side chain family, and the altered antibodies can be tested for their ability to bind to antigen using the functional assays described herein.

[0037] Costimulatory Ligand: As used herein, the term "costimulatory ligand" refers to a molecule on an antigen-presenting cell (e.g., an APC, a dendritic cell, a B cell, etc.) that specifically binds to a cognate costimulatory molecule on an immune cell (e.g., a T lymphocyte), thereby providing a signal that mediates an immune cell response, including, but not limited to, proliferation, activation, differentiation, etc. Costimulatory ligands may include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), CD28, PD-L1, PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM; lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonists or antibodies that bind to Toll ligand receptors, and ligands that specifically bind to B7-H3. Costimulatory ligands also include antibodies that specifically bind to costimulatory molecules present on immune cells (e.g., T lymphocytes), such as, but not limited to, ligands that specifically bind to CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83, among others.

[0038] Cytotoxicity: As used herein, the term "cytotoxic" or "cytotoxicity" refers to killing or damaging a cell. In one embodiment, the cytotoxicity of a metabolically enhanced cell is improved, e.g., the cytolytic activity of an immune cell (e.g., T lymphocyte) is increased.

[0039] Effective amount: As used herein, the term "effective amount" refers to a dose appropriate for preventing or treating a neoplastic disease, such as cancer, in an individual. The effective amount for therapeutic or prophylactic use depends, for example, on the stage and severity of the disease or disorder being treated, the age, weight, and general health of the patient, and the judgment of the prescribing physician. The size of the dose will also be determined by the selected activity, the method of administration, the timing and frequency of administration, the existence, nature, and extent of any adverse side effects that may accompany the administration of a particular active ingredient, and the desired physiological effect. Those skilled in the art will understand that various diseases or disorders may require long-term treatment with multiple administrations, possibly using the genetically engineered cells (e.g., CAR cells) of the present disclosure, in each round or in various rounds of administration, with short intervals between each round, e.g., with edited hematopoietic stem cells, as described herein.

[0040] For purposes of the present invention, the amount or dose of genetically engineered cells comprising a heterologous nucleic acid containing a CAR construct described herein administered should be sufficient to produce a therapeutic or prophylactic response in the subject or animal over a reasonable time frame. For example, the dose should be sufficient to bind to an antigen or detect, treat, or prevent cancer for a period of at least about 2 hours, e.g., at least about 12 to about 24 hours, from the time of administration. In certain embodiments, the period may be longer. The dose will be determined by the efficacy of the particular genetically engineered cells (e.g., CAR cells) of the present disclosure and the condition of the animal (e.g., human), as well as the body weight of the animal (e.g., human) being treated.

[0041] Effector function: As used herein, "effector function" or "effector activity" refers to a specific activity carried out by an immune cell in response to stimulation of the immune cell. For example, the effector function of a T lymphocyte involves recognizing an antigen and killing cells expressing the antigen.

[0042] Endogenous: As used herein, "endogenous" refers to any substance that is derived from or produced within a particular organism, cell, tissue, or system.

[0043] Exogenous: As used herein, the term "exogenous" refers to any substance that is introduced from or produced outside a particular organism, cell, tissue, or system.

[0044] Expand: As used herein, the term "expand" refers to increasing in number, as in increasing the number of cells, e.g., immune cells, e.g., T lymphocytes, B lymphocytes, NK cells, and / or hematopoietic cells. In one embodiment, immune cells, e.g., T lymphocytes, B lymphocytes, NK cells, and / or hematopoietic cells, that are expanded ex vivo are increased in number compared to the number originally present in the culture. In another embodiment, immune cells, e.g., T lymphocytes, B lymphocytes, NK cells, and / or hematopoietic cells, that are expanded ex vivo are increased in number compared to other cell types in the culture. In some embodiments, expansion can occur in vivo. As used herein, the term "ex vivo" refers to cells that have been removed from an organism (e.g., a human) and grown outside of the organism (e.g., in a culture dish, test tube, or bioreactor).

[0045] Functional portion: As used herein, the term "functional portion," when used in reference to a CAR, refers to any portion or fragment of a CAR construct of the invention, which portion or fragment retains the biological activity of the CAR construct of which it is a part (parent CAR construct). Functional portions include, for example, those portions of a CAR construct that retain the ability to recognize target cells or detect, treat, or prevent cancer to a similar extent, the same extent, or a greater extent than the parent CAR construct. With respect to a parent CAR construct, the functional portion can constitute, for example, about 10%, about 25%, about 30%, about 50%, about 68%, about 80%, about 90%, about 95%, or more of the parent CAR.

[0046] A functional portion can include additional amino acids at the amino or carboxy terminus, or at both termini, of the portion, which are not found in the amino acid sequence of the parent CAR construct. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, such as recognizing target cells, detecting cancer, treating or preventing cancer, etc. More desirably, the additional amino acids enhance the biological activity compared to the biological activity of the parent CAR construct.

[0047] Functional variant: As used herein, the term "functional variant" refers to a CAR construct, polypeptide, or protein that has substantial or significant sequence identity or similarity with a parent CAR construct, and the functional variant retains the biological activity of the CAR of which it is a variant. Functional variants include, for example, variants of the CAR constructs (parent CAR constructs) described herein that retain the ability to recognize target cells to a similar extent, the same extent, or a greater extent than the parent CAR construct. With respect to the parent CAR construct, the functional variant can be, for example, at least about 30%, about 50%, about 75%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more identical in amino acid sequence to the parent CAR construct. A functional variant can, for example, include the amino acid sequence of the parent CAR with at least one conservative amino acid substitution. Alternatively or additionally, the functional variant may comprise the amino acid sequence of the parent CAR construct with at least one non-conservative amino acid substitution. In this case, the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution may enhance the biological activity of the functional variant, resulting in an increase in the biological activity of the functional variant compared to the parent CAR construct.

[0048] gRNA: The terms "gRNA" and "guide RNA" are used interchangeably throughout and refer to a nucleic acid that facilitates specific targeting or homing of a gRNA / Cas9 molecule complex to a target nucleic acid. A gRNA, sometimes referred to herein as an sgRNA, can be unimolecular (having a single RNA molecule) or modular (comprising more than one, typically two separate RNA molecules). A gRNA may bind to a target domain in the genome of a host cell. The gRNA (e.g., its targeting domain) may be partially or fully complementary to the target domain. A gRNA may also contain a "scaffold sequence" (e.g., a tracrRNA sequence) that recruits a Cas9 molecule to a target domain bound to the gRNA sequence (e.g., by the targeting domain of the gRNA sequence). The scaffold sequence may contain at least one stem-loop structure and recruit an endonuclease. Exemplary scaffold sequences can be found, for example, in Jinek, et al. I(2012)337(6096):816-821, Ran, et al. Nature Protocols(2013)8:2281-2308, PCT Publication No. WO2014 / 093694, and PCT Publication No. WO2013 / 176772.

[0049] Heterologous: As used herein, the term "heterologous" refers to a phenomenon that occurs in an ecosystem, e.g., a cell, and does not naturally occur in that system. For example, expression of a protein in a cell in which the protein does not naturally occur in that cell (e.g., the cell does not naturally encode the protein) is heterologous expression of the protein. In some embodiments, the heterologous nucleic acid encodes a chimeric antigen receptor construct.

[0050] Immune cell: As used herein, the term "immune cell," which is used interchangeably herein with the term "immune effector cell," refers to a cell that is involved in an immune response, e.g., promoting an immune response. Examples of immune cells include, but are not limited to, T lymphocytes, natural killer (NK) cells, macrophages, monocytes, dendritic cells, neutrophils, eosinophils, mast cells, platelets, large granular lymphocytes, Langerhans cells, or B lymphocytes. A source of immune cells (e.g., T lymphocytes, B lymphocytes, NK cells) can be obtained from a subject.

[0051] Immune response: As used herein, the term "immune response" refers to a cellular and / or systemic response to an antigen that occurs when lymphocytes identify the antigen molecule as foreign, induce the formation of antibodies, and / or activate lymphocytes to eliminate the antigen.

[0052] Mobilized cells / lymphocytes: As used herein, the term "mobilized cells" refers to cells obtained from a blood sample (e.g., an apheresis sample) from a subject who has undergone hematopoietic stem cell mobilization. In contrast, "steady-state cells" refers to cells obtained from a blood sample (e.g., an apheresis sample) from a subject who has not undergone hematopoietic stem cell mobilization. For example, as shown in Figures 3E and 3H, the relative populations of cell types and the developmental state of the cells differ between the steady-state and mobilized samples. In some embodiments, the mobilized cell population contains a higher proportion of B cells (B lymphocytes) compared to the steady-state cell population. In some embodiments, the mobilized cell population contains a lower proportion of T cells (T lymphocytes) than the steady-state cells. In some embodiments, the mobilized cells contain a higher proportion of naive T cells than the steady-state cells. In some embodiments, the mobilized cells contain a lower proportion of one, two, or all of central memory T cells (TCM), effector memory T cells (TEM), or T cell effectors than the steady-state cells. As used herein, the term "mobilized lymphocytes" refers to lymphocytes (or their progeny) obtained from a subject who has undergone hematopoietic stem cell mobilization. Hematopoietic stem cell mobilization techniques and protocols are routinely used in clinical settings, and exemplary techniques and protocols suitable according to embodiments of the present disclosure include protocols utilizing etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony-stimulating factor (G-CSF). Some exemplary protocols are provided herein, and additional suitable protocols will be apparent to those skilled in the art. Some exemplary suitable protocols include those listed in Albakri et al., "A Review of Advances in Hematopoietic Stem Cell Mobilization and the Potential Role of Notch2 Blockade," Cell Transplant 2020, 29:0963689720947146.

[0053] Nucleic Acid: As used herein, the term "nucleic acid" refers to a polymer of at least three nucleotides. In some embodiments, nucleic acids include DNA. In some embodiments, nucleic acids include RNA. In some embodiments, nucleic acids are single-stranded. In some embodiments, nucleic acids are double-stranded. In some embodiments, nucleic acids include both single-stranded and double-stranded portions. In some embodiments, nucleic acids include a backbone containing one or more phosphodiester linkages. In some embodiments, nucleic acids include a backbone containing both phosphodiester and non-phosphodiester linkages. For example, in some embodiments, nucleic acids may include a backbone containing, e.g., one or more phosphorothioate or 5'-N-phosphoramidite linkages, and / or one or more peptide linkages, e.g., as in "peptide nucleic acids." In some embodiments, nucleic acids include one or more or all of the naturally occurring residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, nucleic acids include one or more or all of the non-naturally occurring residues. In some embodiments, the non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalating bases, and combinations thereof). In some embodiments, the non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to that of the natural residue. In some embodiments, the nucleic acid has a nucleotide sequence that encodes a functional gene product, such as an RNA or a polypeptide.In some embodiments, a nucleic acid has a nucleotide sequence that includes one or more introns. In some embodiments, a nucleic acid can be prepared by isolation from a natural source, enzymatic synthesis (e.g., polymerization based on a complementary template in vivo or in vitro, replication in a recombinant cell or system, or chemical synthesis, etc. In some embodiments, a nucleic acid has at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 8 and 0, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues in length.

[0054] Single-chain antibody: As used herein, the term " single-chain antibody " refers to the antibody that is produced by recombinant DNA technology, and the immunoglobulin heavy chain fragment and light chain fragment are linked to Fv region through the engineered range of amino acids.Various methods for producing single-chain antibody are known, and include the method described in U.S. Patent No. 4,694,778; Bird (1988) Science 242:423-442; Huston et al. (1988) Proc.Natl.Acad.Sci.USA 85:5879-5883; Ward et al. (1989) Nature 334:54454; Skerra et al. (1988) Science 242:1038-1041.

[0055] Specific binding: As used herein, the term "specific binding" with respect to an antigen-binding domain, such as an antibody agent or a portion of a chimeric antigen receptor, refers to an antigen-binding domain or antibody agent that recognizes a specific antigen but does not substantially recognize or bind other molecules in a sample. For example, an antigen-binding domain or antibody agent that specifically binds to an antigen from one species may also bind to that antigen from one or more species. However, such cross-species reactivity does not, in itself, change the classification of the antigen-binding domain or antibody agent as specific. In another example, an antigen-binding domain or antibody agent that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross-reactivity does not, in itself, change the classification of the antigen-binding domain or antibody agent as specific. In some cases, the terms "specific binding" or "specifically binds" can be used in reference to the interaction of an antigen-binding domain or antibody agent, protein, or peptide with a second chemical species, meaning that the interaction is dependent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species, for example, an antigen-binding domain or antibody agent recognizes and binds to a particular protein structure rather than proteins in general. If an antigen-binding domain or antibody agent is specific for epitope "A," the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of labeled A bound to the antibody in a reaction containing labeled "A" and the antigen-binding domain or antibody agent.

[0056] Subject: As used herein, the term "subject" refers to an organism, e.g., a mammal (e.g., a human, a non-human mammal, a non-human primate, a primate, a laboratory animal, a mouse, a rat, a hamster, a gerbil, a cat, or a dog). In some embodiments, the human subject is an adult, an adolescent, or a pediatric subject. In some embodiments, the subject is afflicted with a disease, disorder, or condition, e.g., a disease, disorder, or condition that can be treated as provided herein, e.g., a cancer or tumor listed herein. In some embodiments, the subject is susceptible to the disease, disorder, or condition; in some embodiments, a susceptible subject is predisposed to and / or exhibits an increased risk of developing the disease, disorder, or condition (compared to the average risk observed in a reference subject or population). In some embodiments, the subject exhibits one or more symptoms of the disease, disorder, or condition. In some embodiments, the subject does not exhibit a particular symptom (e.g., a clinical symptom of the disease) or characteristic of the disease, disorder, or condition. In some embodiments, the subject does not exhibit any symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the subject is a patient. In some embodiments, the subject is an individual who will be and / or has been administered a diagnosis and / or therapy.

[0057] Target: As used herein, the term "target" refers to a cell, tissue, organ, or site in the body that is the subject of the provided methods, systems, and / or compositions, e.g., a cell, tissue, organ, or site in the body that is in need of treatment or that is preferentially bound by, e.g., a CAR described herein.

[0058] T cell receptor: As used herein, the term "T cell receptor" or "TCR" refers to a complex of membrane proteins involved in the activation of T cells (interchangeably referred to as T lymphocytes) in response to antigen presentation. TCRs are responsible for recognizing antigens bound to major histocompatibility complex molecules. TCRs comprise a heterodimer of alpha (α) and beta (β) chains, although in some cells, TCRs comprise gamma and delta (γ / δ) chains. TCRs may exist in alpha / beta and gamma / delta forms, which are structurally similar but differ in anatomical location and function. Each chain comprises two extracellular domains: a variable domain and a constant domain. In some embodiments, TCRs may be engineered on any cell that contains a TCR, including, for example, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, and gamma delta T cells. In some embodiments, the T lymphocytes are alpha / beta T lymphocytes. In some embodiments, the T lymphocytes are gamma / delta T lymphocytes.

[0059] Therapeutic: As used herein, the term "therapeutic" means treatment and / or prophylaxis. A therapeutic effect is achieved by suppression, amelioration, or eradication of a disease state.

[0060] Transfected: As used herein, the terms "transfected" or "transformed" or "transduced" refer to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" cell, or a "transformed" cell, or a "transduced" cell, is a cell that has been transfected, transformed, or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

[0061] Transgene: As used herein, the term "transgene" refers to an exogenous nucleic acid sequence contained within a cell, e.g., within the genome of a cell, where the nucleic acid sequence does not naturally occur. In some embodiments, a transgene can comprise or consist of a nucleic acid sequence encoding a gene product, e.g., a CAR. In some embodiments, a transgene can comprise or consist of an expression construct, e.g., a nucleic acid sequence encoding a gene product under the control of a regulatory element, e.g., a promoter.

[0062] Treatment: As used herein, the terms "treat," "treatment," or "treating" refer to partial or complete alleviation, amelioration, delay in onset, inhibition, prevention, reduction, and / or reduction in the incidence and / or severity of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject who does not exhibit signs or characteristics of a disease, disorder, and / or condition (e.g., may be prophylactic). In some embodiments, treatment may be administered to a subject who exhibits only early or mild signs or characteristics of a disease, disorder, and / or condition, e.g., for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject who exhibits established, severe, and / or end-stage signs of a disease, disorder, or condition. In some embodiments, treating may include administering immune cells to a subject, including genetically engineered cells expressing a CAR (e.g., T lymphocytes, B lymphocytes, NK cells), or administering a hematopoietic stem cell transplant to a subject, including genetically engineered stem cells.

[0063] Tumor: As used herein, the term "tumor" refers to an abnormal growth of cells or tissues. In some embodiments, a tumor may contain cells that are precancerous (e.g., benign), malignant, premetastatic, metastatic, and / or non-metastatic. In some embodiments, a tumor is associated with or is a sign of cancer. In some embodiments, a tumor may be a dispersed tumor or a liquid tumor. In some embodiments, a tumor may be a solid tumor.

[0064] genetically engineered cells Some aspects of the present disclosure provide cells, e.g., mobilized lymphocytes or their progeny, e.g., T lymphocytes, B lymphocytes, NK cells, that comprise a heterologous nucleic acid comprising a transgene encoding a CAR. In some embodiments, the cells or their progeny are lymphocytes obtained from a subject after hematopoietic stem cell mobilization.

[0065] In some embodiments, the transgene encodes a chimeric antigen receptor that targets a human antigen associated with a disease or disorder, for example, a lineage-specific cell surface antigen associated with a hyperproliferative disease. In some embodiments, the CAR is operably linked to a cell-type specific promoter or a constitutive promoter. In some embodiments, the cell-type specific promoter is a CD8 promoter. In some embodiments, the cell-type specific promoter is a CD3 delta promoter. In some embodiments, the cell-type specific promoter is a CD56 promoter. In some embodiments, the cell-type specific promoter is a CD244 promoter. In some embodiments, the cell-type specific promoter is a CD94 promoter. In some embodiments, the cell-type specific promoter is an NKG2D promoter.

[0066] In some embodiments, the transgene encodes a chimeric antigen receptor comprising a binding domain, a hinge domain, a transmembrane domain, at least one costimulatory domain, a cytoplasmic signaling domain, or a combination thereof. In some embodiments, the binding domain comprises an antibody or antigen-binding antibody fragment that binds to the antigen. In some embodiments, the binding domain comprises an scFv or single-domain antibody that binds to the antigen. In some embodiments, the antigen is a lineage-specific cell surface antigen. In some embodiments, expression of the antigen is associated with a hyperproliferative disease. In some embodiments, the hyperproliferative disease is a hematopoietic malignancy, such as a myeloid or lymphoid malignancy. In some embodiments, the lineage-specific cell surface antigen is CD33, CD123, CD19, CLL-1, CD30, CD38, BCMA, CD5, CD6, CD7, or any other lineage-specific cell surface antigen, such as those described herein. In some embodiments, the hinge domain of the CAR is a CD8α (CD8 alpha) hinge domain. In some embodiments, the transmembrane domain of the CAR is a CD8 or CD28 transmembrane domain. In some embodiments, the costimulatory domain of the CAR is a 4-1BB or CD28 costimulatory domain, or a combination thereof. In some embodiments, the cytoplasmic signaling domain of the CAR is a CD3ζ (CD3 zeta) cytoplasmic signaling domain.

[0067] In some embodiments, the cell is a lymphocyte cell. In some embodiments, the cell is a T cell, also referred to as a T lymphocyte. In some embodiments, the cell is an alpha / beta T cell. In some embodiments, the cell is a gamma / delta T cell. In some embodiments, the cell is a natural killer (NK) cell. In some embodiments, the cell is a natural killer T cell (NKT cell). In some embodiments, the T lymphocyte is a naive T lymphocyte, an effector T lymphocyte, a memory T lymphocyte, or a regulatory T lymphocyte. In some embodiments, the cell is a B cell, also referred to as a B lymphocyte.

[0068] In some embodiments, the immune effector cells provided herein are T lymphocytes, which may be characterized by expression of CD3 (i.e., CD3+). In some embodiments, the T cells express T cell receptor (TCR) α and β chains. In some embodiments, the T cells express TCR γ and TCR δ chains. T lymphocytes may be further classified based on the expression of other cell surface markers, such as CD4 or CD8. Expression of CD4 or CD8 broadly classifies T cells as "T helper cells," characterized by expression of CD4 (CD4+), or "cytotoxic T cells," characterized by expression of CD8 (CD8+). As will be understood by those skilled in the art, CD4+ T cells and CD8+ T cells have distinct cellular functions. In some embodiments, the T cells are CD4+ T cells, which may be further distinguished as Th1 or Th2 CD4+ cells. In some embodiments, the T cells are CD8+ T cells (also called cytotoxic T lymphocytes, CTLs, or CD8 T cells).

[0069] In some embodiments, the T cells are cytotoxic T cells. In some embodiments, the T cells are central memory T cells (TCM), stem memory T cells (TSCM), stem cell-like memory T cells (or stem-like memory T cells), and effector memory T cells, e.g., TEM cells and TEMRA (CD45RA+) cells, effector T cells, or T helper cells, e.g., Th1 cells, Th2 cells, Th9 cells, Th17 cells, Th22 cells, Tfh (follicular helper) cells, T regulatory cells (Tregs, FoxP3+ T cells), natural killer T cells (NKT cells), mucosal-associated invariant T cells (MAIT), and γδ T cells. In some embodiments, the T cells express a death ligand, such as PD1. In some embodiments, T cells, such as CD8+ T cells, that express PD1 are considered "exhausted" T cells and promote immunosuppression.

[0070] In some embodiments, the immune effector cells provided herein are T lymphocytes, which may be characterized by expression of CD19 (i.e., CD19+). In some embodiments, the immune effector cells provided herein are NK cells, which may be characterized by expression of CD56 (i.e., CD56+).

[0071] In some embodiments, the cells of the present disclosure are mobilized lymphocytes. In some embodiments, the cells, e.g., mobilized lymphocytes, used in the methods of the present disclosure are collected from a subject who has undergone hematopoietic stem cell mobilization. In some embodiments, the cells of the present disclosure are peripheral blood mononuclear cells (PBMCs), e.g., lymphocytes, obtained from a subject who has undergone hematopoietic stem cell mobilization. Hematopoietic stem cell mobilization is a process in which a subject is exposed to a mobilizing agent to promote the mobilization of cells normally located in the bone marrow (e.g., hematopoietic stem cells) into the peripheral blood circulation, allowing the stem cells to be collected by collecting a blood sample, e.g., an apheresis sample. See, e.g., Karpova D, Rettig MP, DiPersio JF. Mobilized peripheral blood: an updated perspective. F1000Res. 2019;8:F1000 Faculty Rev-2125. Published December 20, 2019, doi:10.12688 / f1000research.21129.1. In some embodiments, hematopoietic stem cell mobilization comprises administering to the subject one or more of etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony-stimulating factor (G-CSF). In some embodiments, hematopoietic stem cell mobilization comprises expanding a hematopoietic stem cell population in the subject. In some embodiments, a blood sample (e.g., an apheresis sample) taken from a subject who has undergone hematopoietic stem cell mobilization comprises a different relative proportion of cell types (e.g., relative to total cell count) compared to a blood sample (e.g., an apheresis sample) taken from a steady-state subject who has not undergone hematopoietic stem cell mobilization.

[0072] In some embodiments, a blood sample from a subject who has undergone hematopoietic stem cell mobilization can provide mobilized lymphocytes (e.g., for generating engineered cells comprising a heterologous nucleic acid encoding a CAR-targeted lineage-specific cell surface antigen associated with a hyperproliferative disease) and HSCs (e.g., for generating engineered HSCs described herein). Methods of hematopoietic stem cell mobilization and methods of obtaining HSCs are described, for example, in PCT Application No. US2016 / 057339, which is incorporated herein by reference in its entirety.

[0073] In some embodiments, the mammalian subject is a non-human primate, rodent (e.g., mouse or rat), cow, pig, horse, or livestock. In some embodiments, the mobilized lymphocytes and / or HSCs are obtained from a human subject, such as a human subject with a hematopoietic malignancy. In some embodiments, the mobilized lymphocytes and / or HSCs are obtained from a healthy donor. In some embodiments, the mobilized lymphocytes and / or HSCs are obtained from a subject to whom immune cells expressing the chimeric receptor will later be administered. Mobilized lymphocytes administered to the same subject from whom the cells were obtained are referred to as autologous cells, while mobilized lymphocytes obtained from a subject other than the subject to whom the cells will later be administered are referred to as allogeneic cells.

[0074] Specific populations of cells or cell types may be isolated from the mobilized lymphocyte cell population. In some embodiments, T cells are isolated by methods well known in the art, including commercially available isolation methods (see, e.g., Rowland-Jones et al., Lymphocytes: A Practical Approach, Oxford University Press, New York (1999)).T cell separation and isolation methods are well known in the art. For example, T cells can be isolated using various cell surface markers or combinations of markers (including positive and negative selection) depending on the desired T cell subtype, including, but not limited to, CD3, CD4, CD8, CD34 (for hematopoietic stem and progenitor cells), as is well known in the art, and can be used to separate cells (Kearse, T Cell Protocols: Development and Activation, Humana Press, Totowa NJ (2000); De Libero, T Cell Protocols, Vol. 514 of Methods in Molecular Biology, Humana Press, Totowa NJ (2009); Su et al., Methods Mol. Biol. 806:287-299 (2012); Bluestone et al., Methods Mol. Biol. 806:287-299 (2012)). al.,Sci.Transl.Med.7(315)(doi:10.1126 / scitranslmed.aad4134)(2015), Miyara et al.,Nat.Rev.Rheumatol.10:543-551(2014), Liu et al. al.,J.Exp.Med.203:1701-1711(2006), Seddiki et al.,J.Exp.Med.203:1693-1700(2006), Ukena et al.,Exp.Hematol.39:1152-1160(2011), Chen et al. al., J. Immunol. 183:4094-4102 (2009), Putnam et al., Diabetes 58:652-662 (2009); Putnam et al., Am. Transplant. 13:3010-3020 (2013); Lee et al., Cancer Res. 71:2871-2881 (2011); MacDonald et al., J Clin. Invest. 126:1413-1424 (2016)).Methods for isolating and expanding regulatory T cells are also commercially available (e.g., BD Biosciences, San Jose, Calif.; STEMCELL Technologies Inc., Vancouver, Canada; eBioscience, San Diego, Calif.; Invitrogen, Carlsbad, Calif.).

[0075] In some embodiments, the engineered cell (or its progeny) is autologous to the subject to whom it is administered again, e.g., after contacting with a heterologous nucleic acid encoding a CAR. In some embodiments, the cell is non-autologous, e.g., allogeneic to the subject to whom it is administered, e.g., after contacting with a heterologous nucleic acid encoding a CAR.

[0076] In some embodiments, recruited cells (e.g., recruited lymphocytes) are obtained from a subject, genetically engineered to express a CAR, and then administered back to the same subject. In some embodiments, recruited cells (e.g., recruited lymphocytes) are obtained from a subject, genetically engineered to express a CAR, and then administered to a different subject, e.g., an HLA-matched subject.

[0077] Any suitable method for isolating a specific cell type (e.g., T lymphocytes, B lymphocytes, NK cells) from a cell population (e.g., mobilized PBMCs) that can be used for recombinant expression of a CAR can be used, including, but not limited to, methods known in the art, such as those described in Sadelain et al., Nat. Rev. Cancer 3:35-45 (2003); Morgan et al., Science 314:126-129 (2006), Panelli et al., J Immunol. 164:495-504 (2000); Panelli et al., J Immunol. 164:4382-4392 (2000)), Dupont et al., Cancer Res. 65:5417-5427 (2005); Papanicolaou et al., Blood 102:2498-2505 (2003)).

[0078] Delivery of heterologous nucleic acids encoding CARs targeting lineage-specific cell surface antigens provided herein to cells can be performed via any suitable method or technique. For example, viral vector systems are particularly suitable for introducing nucleic acids into mature cells, although other delivery modes can also be used. Other methods for creating targeted integration are known in the art and include, but are not limited to, the use of transposons or viral vectors (e.g., AAV vectors) that exhibit site specificity or site preference for integration into the genome of a host cell. While several exemplary delivery methods for cell-type-specific inducible expression systems are provided herein, additional suitable systems will be apparent to those skilled in the art based on this disclosure and knowledge in the art. The disclosure is not limited in this respect.

[0079] Expression constructs Expression constructs suitable for expressing chimeric antigen receptors in effector lymphocytes, such as T lymphocytes, B lymphocytes, or NK cells, are known in the art. Some exemplary expression constructs are provided herein, and those skilled in the art will recognize additional suitable constructs. Typically, a suitable expression construct comprises a nucleic acid sequence encoding a CAR under the control of a heterologous promoter. In some embodiments, the promoter is a constitutively active promoter. In some embodiments, the promoter is a cell-type-specific promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the expression construct comprises additional elements, such as, for example, a polyadenylation signal, 5'UTR and / or 3'UTR sequences, intron sequences, etc. Depending on the route of delivery of the expression construct to target cells, e.g., lymphocytes, the expression construct may comprise additional elements, such as viral packaging and integration elements in the case of viral delivery.

[0080] Some aspects of the present disclosure provide heterologous nucleic acids and their expression constructs useful for expressing transgenes, such as CARs, in specific cell types. For example, some aspects of the present disclosure provide expression constructs that are active only in specific cell types or subtypes (e.g., T lymphocytes, T progenitor cells, mature T lymphocytes, NK cells, B lymphocytes, etc.). In some embodiments, cell-type-specific and inducible expression is achieved by cell-type-specific expression of an inducible expression system, for example, by placing one of the components of the inducible system under the control of a regulatory element, such as a promoter, that is active only in the respective cell type.

[0081] In some embodiments, the promoter for expressing the CAR is under the control of a cell type specific promoter, which is a promoter that is expressed in one particular cell type, e.g., T lymphocytes, B lymphocytes, NK cells, or a particular subgroup of cells, e.g., lymphocytes, but not in cells other than the particular cell type.

[0082] In some embodiments, the CAR comprises an antigen binding domain that binds to an antigen associated with a disease or disorder, e.g., associated with a hyperproliferative disease or disorder.

[0083] In some embodiments, the CAR is a first-generation CAR. In some embodiments, the CAR is a second-generation CAR. In some embodiments, the CAR is a third-generation CAR. In some embodiments, the CAR is a fourth- or fifth-generation CAR, or an armored CAR. Exemplary CAR constructs are provided herein; additional suitable CAR constructs will be apparent to those skilled in the art based on this disclosure and knowledge in the art. For descriptions of various CAR scaffolds or frameworks suitable for use in connection with the expression systems provided herein, see the following exemplary and non-limiting publications: Sadelain et al., Cancer Discov. 3(4):388-398 (2013); Jensen et al., Immunol. Rev. 257:127-133 (2014); Sharpe et al., Dis. Model Mech. 8(4):337-350 (2015); Brentjens et al., Clin. Cancer Res. 13:5426-5435 (2007); Gade et al., Cancer Res. 65:9080-9088 (2005); Maher et al., Nat. Biotechnol. 20:70-75 (2002); Kershaw et al. al., J. Immunol. 173:2143-2150 (2004); Sadelain et al., Curr. Opin. Immunol. (2009); Hollyman et al., J. Immunother. 32: 169-180 (2009)).

[0084] First-generation CARs typically consist of an extracellular antigen-binding domain, e.g., a single-chain variable fragment (scFv) fused to a transmembrane domain fused to the cytoplasmic / intracellular domain of a T cell receptor chain. Typically, first-generation CARs contain the intracellular domain of CD3ζ, which transduce signals from the endogenous T cell receptor (TCR). "First-generation" CARs can provide de novo antigen recognition independent of HLA-mediated antigen presentation and can trigger activation of both CD4+ and CD8+ T cells via their CD3ζ chain signaling domain in a single fusion molecule.

[0085] Second-generation CARs comprise an antigen binding domain fused to an intracellular signaling domain that can activate T cells, and a costimulatory domain designed to enhance the efficacy and persistence of T cells. See, for example, Sadelain et al., Cancer Discov. 3:388-398, 2013. Second-generation CARs comprise an intracellular costimulatory domain, such as CD28, 4-1BB, ICOS, OX40, or a similar costimulatory domain, in addition to the CD3ζ domain. Thus, second-generation CARs provide both costimulation, for example, by the CD28 or 4-1BB domain, and activation, for example, by the CD3ζ signaling domain. Compared with first-generation CARs, second-generation CARs can improve the anti-tumor activity of T cells.

[0086] Third generation CARs comprise two or more costimulatory domains, for example, two costimulatory domains, for example, both a CD28 domain and a 4-1BB domain, and an activation domain, for example, by including a CD3ζ activation domain.

[0087] Generally, a CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular domain. Typically, the antigen-binding domain binds to an antigen of interest, such as an antigen associated with a disease or disorder, e.g., a neoplastic or malignant disease or disorder. In some embodiments, the antigen-binding domain is an antibody or an antigen-binding fragment thereof. In some embodiments, the antigen-binding domain is a single-chain antibody or an antigen-binding fragment thereof. In some embodiments, the antigen-binding domain comprises an scFv. In some embodiments, the antigen-binding domain comprises a single-domain antibody, e.g., a camelid antibody, or a humanized derivative thereof. In some embodiments, the antigen-binding domain comprises a receptor or receptor ligand.

[0088] Some exemplary CARs for use in the expression systems disclosed herein are provided herein. Additional CARs will be apparent to those skilled in the art based on this disclosure, taking into account the knowledge of the art in CAR design, for example, as shown in: Sadelain et al., Cancer Discov.3(4):388-398(2013); Jensen et al., Immunol.Rev.257:127-133(2014); Sharpe et al., Dis.Model Mech.8(4):337-350(2015), and the references cited therein.

[0089] In some embodiments, a CAR for use in the present invention comprises an extracellular domain comprising an antigen-binding domain that binds to a lineage-specific cell surface antigen, e.g., associated with a hyperproliferative disease. In some embodiments, the antigen-binding domain binds to a lineage-specific cell surface antigen expressed on the surface of a neoplastic or malignant cell. In some embodiments, the antigen-binding domain binds to a lineage-specific cell surface antigen expressed or present on the surface of a pathogenic or pathological cell, e.g., a cell infected by an infectious agent or a cell characterized by a pathogenic or pathological state. In some embodiments, the antigen-binding domain may be an scFv or Fab, a single-domain antibody, or any suitable antigen-binding fragment of an antibody (see Sadelain et al., Cancer Discov. 3:38-398 (2013)).

[0090] In some embodiments, the antigen-binding domain comprises the sequence of a human, humanized, chimeric, or CDR-grafted antibody, or antigen-binding antibody fragment. In some embodiments, the antigen-binding domain comprises an scFv. Exemplary scFvs are provided herein, and additional suitable scFvs will be apparent to those of skill in the art based on this disclosure and knowledge of the art related to scFvs (see, e.g., Huston, et al., Proc. Nat. Acad. Sci. USA 85:5879-5883 (1988); Ahmad et al., Clin. Dev. Immunol. 2012:ID980250 (2012); U.S. Patent Nos. 5,091,513, 5,132,405, and 4,956,778; and U.S. Patent Application Publication Nos. 20050196754 and 20050196754). The present disclosure is not limited in this respect.

[0091] Instead of using an antigen-binding domain derived from an antibody, the CAR extracellular domain may comprise a ligand or extracellular ligand-binding domain of a receptor (see Sadelain et al., Cancer Discov. 3:388-398 (2013); Sharpe et al., Dis. Model Mech. 8:337-350 (2015)).

[0092] In some embodiments, CAR binds to an antigen expressed on malignant cells, which is sometimes referred to as a cancer antigen.Any CAR that targets a suitable cancer antigen can be used in conjunction with the expression system of the present disclosure.Exemplary cancer antigens and exemplary cancers are provided below.

[0093] In some embodiments, the lineage-specific cell surface antigen is selected from: CD5, CD6, CD7, CD13, CD19, CD22, CD20, CD25, CD30, CD32, CD38, CD44, CD45, CD47, CD56, 96, CD117, CD123, CD135, CD174, CLL-1, BCMA, folate receptor beta, IL1RAP, MUC1, NKG2D / NKG2DL, TIM-3, or WT1.

[0094] In some embodiments, the lineage-specific cell surface antigen is CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD16, CD16b, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32a, CD32b , CD32c, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, C D48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD61, CD62E, CD62L, CD62P, CD63, C D64a, CD65, CD65s, CD66a, CD66b, CD66c, CD66F, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD 84, CD85A, CD85C, CD85D, CD85E, CD85F, CD85G, CD85H, CD85I, CD85J, CD85K, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD 98, CD99, CD99R, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107a, CD107b, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, C D117, CD118, CD119, CD120a, CD120b, CD121a, CD121b, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD129, CD130, CD131, CD132, CD133,CD134、CD135、CD136、CD137、CD138、CD139、CD140a、CD140b、CD141、CD142、 CD143、CD14、CDw145、CD146、CD147、CD148、CD150、CD152、CD152、CD153、CD1 54, CD155, CD156a, CD156b, CD156c, CD157, CD158b1, CD158b2, CD158d, CD158e1 / e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, CD159c 、CD160、CD161、CD163、CD164、CD165、CD166、CD167a、CD168、CD169、CD170、 CD171、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177 、CD178、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186 、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CDw198、CDw199、CD200、 CD201、CD202b、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210a 、CDw210b、CD212、CD213a1、CD213a2、CD215、CD217、CD218a、CD218b、CD220、 CD221、CD222、CD223、CD224、CD225、CD226、CD227、CD228、CD229、CD230、CD 231、CD232、CD233、CD234、CD235a、CD235b、CD236、CD236R、CD238、CD239、CD 240, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD252, CD253, CD254, CD256, CD257, CD258, CD261, CD262, CD263, CD264, CD265, C D266, CD267, CD268, CD269, CD270, CD272, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD286, CD288CD289, CD290, CD292, CDw293, CD294, CD295, CD296, CD297, CD298, CD299, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD3 04, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD309, CD312, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD324, CD325, CD326, CD327, CD328, CD329, CD331, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD339, CD340, CD344, CD349, CD350, CD351, CD352, CD353, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362 or CD363.

[0095] In some embodiments, the lineage-specific cell surface antigen is selected from the following: CD5, CD6, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD123, CD133, CD138, mesothelin (MSLN), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PCSA), carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 1 (EGF), epithelial glycoprotein 2 (EGF ... Protein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-α and β (FRα and β), ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER-2 / ERB2), epidermal growth factor receptor vIII (EGFRvIII), ERB3, ERB4, human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit alpha-2 (IL-13Rα) 2), kappa-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), L1 cell adhesion molecule (L1CAM), melanoma-associated antigen 1 (melanoma antigen family A1, MAGE-A1), mucin 16 (Muc-16), mucin 1 (Muc-1), NKG2D ligand, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), type 1 tyrosine kinase inhibitor (TYR1) Protein kinase transmembrane receptor 1 (ROR1), B7-H3 (CD276), B7-H6 (Nkp30), chondroitin sulfate proteoglycan-4 (CSPG4), DNAX accessory molecule (DNAM-1), ephrin type A receptor 2 (EpHA2), fibroblast-associated protein (FAP), Gp100 / HLA-A2, glypican 3 (GPC3), HA-1H, HERK-V, IL-11Rα, latent membrane protein 1 (LMP1), neural cell adhesion molecule (N-CAM / CD56), and Trail receptor (TRAIL R). It is understood that these or other cancer antigens can be utilized for targeting by cancer antigen CARs.Although some exemplary suitable CARs and some exemplary suitable CAR target antigens are disclosed herein, additional suitable CARS and CAR target antigens will be apparent to those skilled in the art based on this disclosure in light of the state of the art knowledge regarding CARs and CAR antigens. See, for example, International PCT Application No. PCT / US2017 / 027601, the entire contents of which are incorporated herein by reference. In some embodiments, the CAR binds to a lineage-specific cell surface antigen disclosed herein.

[0096] Genetically engineered hematopoietic stem cells Some aspects of the present disclosure provide genetically engineered hematopoietic stem cells that have been gene-edited to have reduced or absent expression of lineage-specific cell surface antigens, or to have expression of variant forms of lineage-specific cell surface antigens that are not recognized by lineage-specific cell surface-targeting CARs. In some embodiments, the genetically engineered stem cells are administered to a subject in the form of a hematopoietic stem cell transplant.

[0097] In some embodiments, the genetically engineered stem cells provided herein comprise a genomic modification that results in loss of expression of a lineage-specific cell surface antigen, or expression of a variant form of the lineage-specific cell surface antigen that is not recognized by a CAR that targets the lineage-specific cell surface antigen, and do not comprise an expression construct encoding an exogenous protein, e.g., an expression construct encoding a CAR.

[0098] In some embodiments, the genetically engineered hematopoietic stem cells provided herein do not substantially express lineage-specific cell surface antigen proteins, e.g., do not express lineage-specific cell surface antigen proteins that can be measured by a suitable method, such as immunostaining. In some embodiments, the genetically engineered hematopoietic stem cells provided herein do not substantially express wild-type lineage-specific cell surface antigen proteins, but express mutant lineage-specific cell surface antigen variants, e.g., variants that are not recognized by immunotherapeutics that target the lineage-specific cell surface antigen, e.g., CAR-expressing cells, or antibodies, antibody fragments, or antibody-drug conjugates (ADCs) that target the lineage-specific cell surface antigen. In some embodiments, the lineage-specific cell surface antigen is any one of the lineage-specific cell surface antigens described herein.

[0099] In some embodiments, the genetically engineered hematopoietic stem cells provided herein are hematopoietic cells, e.g., hematopoietic stem cells. Hematopoietic stem cells (HSCs) can typically give rise to both myeloid progenitor cells and lymphoid progenitor cells, which further give rise to myeloid cells (e.g., monocytes, macrophages, neutrophils, basophils, dendritic cells, erythrocytes, platelets, etc.) and lymphoid cells (e.g., T cells, B cells, NK cells), respectively. HSCs are characterized by the expression of the cell surface marker CD34 (e.g., CD34+), which can be used to identify and / or isolate HSCs, and the absence of cell surface markers associated with lineage commitment.

[0100] In some embodiments, the populations of genetically engineered hematopoietic stem cells described herein comprise a plurality of genetically engineered hematopoietic stem cells. In some embodiments, the populations of genetically engineered hematopoietic stem cells described herein comprise a plurality of genetically engineered hematopoietic progenitor cells. In some embodiments, the populations of genetically engineered stem cells described herein comprise a plurality of genetically engineered hematopoietic stem cells and a plurality of genetically engineered hematopoietic progenitor cells.

[0101] In some embodiments, the genetically engineered HSCs are obtained from a subject, such as a human subject. Methods for obtaining HSCs are described, for example, in PCT Application No. US2016 / 057339, which is incorporated herein by reference in its entirety. In some embodiments, the HSCs are mobilized from the bone marrow of a subject by administration of a mobilizing agent, e.g., etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony-stimulating factor (G-CSF). In some embodiments, the HSCs are obtained from a human subject, such as a human subject with a hematopoietic malignancy. In some embodiments, the HSCs are obtained from a healthy donor. In some embodiments, the HSCs are obtained from the same subject from which the mobilized lymphocytes were obtained. In some embodiments, the HSCs are obtained from a subject to whom the genetically engineered cells expressing a CAR will later be administered. In some embodiments, the HSCs are obtained from a subject other than the subject to whom the genetically engineered cells expressing a CAR will later be administered. HSCs administered to the same subject from which the cells were obtained are referred to as autologous cells, while HSCs obtained from a subject other than the one to which the cells are administered are referred to as allogeneic cells.

[0102] In some embodiments, the population of genetically engineered hematopoietic stem cells is a heterogeneous population of cells, e.g., a heterogeneous population of genetically engineered hematopoietic stem cells that contain different mutations in lineage-specific cell surface antigens. In some embodiments, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the copies of genes encoding lineage-specific cell surface antigens within the population of genetically engineered hematopoietic stem cells contain mutations introduced by the genome editing approaches described herein, e.g., by a CRISPR / Cas system using the gRNAs provided herein.

[0103] In some embodiments, the genetically engineered hematopoietic cells described herein, such as genetically engineered hematopoietic stem or progenitor cells or genetically engineered immune effector cells, are generated via genome editing techniques, including any technique capable of introducing targeted changes, also referred to as "editing," into the genome of a cell.

[0104] Methods for genetically manipulating hematopoietic stem and / or progenitor cells and immune effector cells will be apparent to those skilled in the art. For example, exemplary methods for genetically manipulating hematopoietic stem and / or progenitor cells are provided in PCT Publication Nos. WO2017 / 066760 and WO2020 / 047164. One exemplary suitable genome editing technology is "gene editing," which involves the use of RNA-guided nucleases, such as CRISPR / Cas nucleases, to introduce targeted single-stranded or double-stranded DNA breaks into the genome of a cell, which triggers cellular repair mechanisms such as non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ, sometimes referred to as "alternative NHEJ" or "alt-NHEJ"), or homology-directed repair (HDR), which typically results in a modified nucleic acid sequence at or immediately adjacent to the site of the nuclease break (e.g., via nucleotide or nucleotide sequence insertion, deletion, inversion, or substitution). See Yeh et al. Nat. Cell. Biol. (2019) 21:1468-1478, e.g., Hsu et al. Cell (2014) 157:1262-1278, Jasin et al. DNA Repair (2016) 44:6-16, Sfeir et al. Trends Biochem. Sci. (2015) 40:701-714.

[0105] Another exemplary genome editing technique is "base editing," which involves the use of base editors, such as nuclease-damaged or partially nuclease-damaged RNA-guided CRISPR / Cas proteins fused to deaminase, which target and deaminate specific nucleic acid bases, such as cytosine or adenosine nucleic acid bases of C or A nucleotides, resulting in a change from a C nucleotide to a T nucleotide or an A nucleotide to a G nucleotide via cellular mismatch repair mechanisms. See, for example, Komor et al. Nature (2016) 533:420-424; Rees et al. Nat. Rev. Genet. (2018) 19(12):770-788; Anzalone et al. Nat. Biotechnol. (2020) 38:824-844.

[0106] Yet another exemplary genome editing technique involves "primed editing," which involves the use of catalytically impaired or partially catalytically impaired RNA-guided nucleases, such as CRISPR / Cas nucleases fused to engineered reverse transcriptase (RT) domains, to introduce new genetic information, such as modified nucleotide sequences, into specifically targeted genomic sites. The Cas / RT fusion also contains a nucleic acid sequence encoding the desired edit and is targeted to the target site within the genome by a guide RNA, which can function as a primer for RT. See, for example, Anzalone et al. Nature (2019) 576(7785):149-157.

[0107] The use of genome editing technology is typically characterized in some embodiments by the use of suitable RNA-guided nucleases, which can be catalytically impaired or partially catalytically impaired, for example, for base editing or prime editing.Examples of suitable RNA-guided nucleases include CRISPR / Cas nucleases.For example, in some embodiments, the suitable RNA-guided nucleases for use in the method for genetically manipulating cells provided herein are Cas9 nucleases, such as SpCas9 or SaCas9 nucleases.For another example, in some embodiments, the suitable RNA-guided nucleases for use in the method for genetically manipulating cells provided herein are Cas12 nucleases, such as Cas12a nucleases. Exemplary suitable Cas12 nucleases include, but are not limited to, AsCas12a, FnCas12a, other Cas12a orthologs, and Cas12a derivatives such as the MAD7 system (MAD7™, Inscripta, Inc.) or Alt-R Cas12a (Cpf1) Ultra nuclease (Alt-R® Cas12a Ultra, Integrated DNA Technologies, Inc.). See, e.g., Gill et al. LIPSCOMB 2017. In United States: Inscripta Inc., Price et al. Biotechnol. Bioeng. (2020) 117(60):1805-1816.

[0108] In some embodiments, the genetically engineered hematopoietic cells described herein (e.g., genetically engineered hematopoietic stem or progenitor cells, or genetically engineered immune effector cells, etc.) are generated by targeting an RNA-guided nuclease, such as a CRISPR / Cas nuclease, such as a Cas9 nuclease or a Cas12a nuclease, to a suitable target site within the genome of the cell under conditions suitable for the RNA-guided nuclease to bind to the target site and cleave the genomic DNA of the cell. A suitable RNA-guided nuclease can be targeted to a specific target site within the genome by a suitable guide RNA (gRNA). Suitable gRNAs for targeting CRISPR / Cas nucleases according to aspects of the present disclosure are provided herein, and exemplary suitable gRNAs are described in more detail elsewhere herein.

[0109] In some embodiments, the lineage-specific cell surface antigen gRNA described herein is complexed with a CRISPR / Cas nuclease, such as a Cas9 nuclease. Various Cas9 nucleases are suitable for use with the gRNA provided herein to produce genome editing according to aspects of the present disclosure. Typically, the Cas nuclease and gRNA are provided in a form and under conditions suitable for the formation of a Cas / gRNA complex that targets a target site on the genome of a cell, for example, a target site within a sequence encoding a lineage-specific cell surface antigen. In some embodiments, a Cas nuclease is used that exhibits the desired PAM specificity to target the Cas / gRNA complex to the desired target domain of the sequence encoding the lineage-specific cell surface antigen. Suitable target domains and corresponding gRNA targeting domain sequences are provided herein.

[0110] In some embodiments, the Cas / gRNA complex is formed, e.g., in vitro, and the target cell is contacted with the Cas / gRNA complex, e.g., via electroporation of the Cas / gRNA complex into the cell. In some embodiments, the cell is contacted separately with a Cas protein and a gRNA, and the Cas / gRNA complex is formed within the cell. In some embodiments, the cell is contacted with a nucleic acid, e.g., DNA or RNA, encoding the Cas protein and / or a nucleic acid encoding the gRNA, or both.

[0111] In some embodiments, the genetically engineered cells provided herein are generated using a suitable genome editing technique characterized by the use of a Cas9 nuclease. In some embodiments, the Cas9 molecule is from or derived from Streptococcus pyogenes (SpCas9), Staphylococcus aureus (SaCas9), or Streptococcus thermophilus (stCas9). Additional suitable Cas9 molecules include those from Neisseria meningitidis (NmCas9), Acidovorax avenae, Actinobacillus pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces spp., cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides spp., Blastopirellula marina, and the like. marina, Bradyrhizobium species, Brevibacillus laterosporus, Campylobacter coli, Campylobacter jejuni (CjCas9), Campylobacter lari, Candidatus Puniceispirillum, Clostridium cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheriae, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, Gammaproteobacteriaproteobacterium, Gluconacetobacter diazotrophicus, Haemophilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicobacter cinaedi, Helicobacter mustelae, Ilyobacter polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria monocytogenes, Listeriaceae bacterium, Methylosinus spp., Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis, Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria meningitidis, Neisseria spp., Neisseria wadsworthii, Nitrosomonas spp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinate succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris, Rhodovulum sp., Simonsiella muerelliSuitable Cas9 nucleases include those derived from or derived from Bacillus subtilis, ...

[0112] In some embodiments, the Cas nuclease is a naturally occurring Cas molecule. In some embodiments, the Cas nuclease is an engineered, altered, or modified Cas molecule that differs, e.g., by at least one amino acid residue, from a reference sequence, e.g., the most similar naturally occurring Cas9 molecule, or a sequence in Table 50 of PCT Publication No. WO2015 / 157070, which is incorporated by reference herein in its entirety.

[0113] In some embodiments, a Cas nuclease belonging to Class 2 Type V of Cas nucleases is used. Class 2 Type V Cas nucleases can be further classified as Type VA, Type VB, Type VC, and Type VU. See, e.g., Stella et al. Nature Structural & Molecular Biology (2017). In some embodiments, the Cas nuclease is a Type VB Cas endonuclease such as C2c1. See, e.g., Shmakov et al. Mol Cell (2015) 60:385-397. In some embodiments, the Cas nuclease used in the genome editing methods provided herein is a Type VA Cas endonuclease such as Cpf1 (Cas12a) nuclease. See, e.g., Strohkendl et al. Mol Cell (2018) 71:1-9. In some embodiments, the Cas nuclease used in the genome editing methods provided herein is a Cpf1 nuclease from Provetella spp., or Francisella spp., Acidaminococcus spp. (AsCpf1), Lachnospiraceae bacterium (LpCpf1), or Eubacterium rectale. In some embodiments, the Cas nuclease is MAD7.

[0114] Both naturally occurring and modified variants of CRISPR / Cas nucleases are suitable for use according to aspects of the present disclosure. For example, dCas or nickase variants, Cas variants with altered PAM specificity, and Cas variants with improved nuclease activity are encompassed by some embodiments of the present disclosure.

[0115] Without wishing to be bound by any particular theory, some features of some exemplary, non-limiting suitable Cas nucleases are described in more detail herein.

[0116] Naturally occurring Cas9 nucleases typically comprise two lobes: a recognition (REC) lobe and a nuclease (NUC) lobe, each of which further comprises domains described, for example, in PCT Publication No. WO2015 / 157070, e.g., at Figures 9A-9B therein (which application is incorporated herein by reference in its entirety).

[0117] The REC lobe contains an arginine-rich bridge helix (BH), a REC1 domain, and a REC2 domain. The REC lobe is thought to be a Cas9-specific functional domain. The BH domain is a long alpha helix and arginine-rich region, encompassing amino acids 60-93 of the S. pyogenes Cas9 sequence. The REC1 domain is involved in recognizing the repeat:anti-repeat duplex of, for example, gRNA or tracrRNA. The REC1 domain contains two REC1 motifs at amino acids 94-179 and 308-717 of the S. pyogenes Cas9 sequence. These two REC1 domains are separated by the REC2 domain in the linear primary structure, but assemble in the tertiary structure to form the REC1 domain. The REC2 domain, or portions thereof, may also play a role in recognizing the repeat:anti-repeat duplex. The REC2 domain encompasses amino acids 180-307 of the S. pyogenes Cas9 sequence.

[0118] The NUC lobe contains a RuvC domain (also referred to herein as a RuvC-like domain), an HNH domain (also referred to herein as an HNH-like domain), and a PAM-interacting (PI) domain. The RuvC domain shares structural similarity with members of the retroviral integrase superfamily and cleaves single strands, e.g., non-complementary strands, of target nucleic acid molecules. The RuvC domain is assembled from three separate RuvC motifs (RuvC I, RuvC II, and RuvC III, often referred to in the art as the RuvCI domain, or the N-terminal RuvC domain, RuvC II domain, and RuvC III domain) at amino acids 1-59, 718-769, and 909-1098 of the Streptococcus pyogenes Cas9 sequence, respectively. Similar to the REC1 domain, the three RuvC motifs are linearly separated by other domains in the primary structure, but in the tertiary structure, the three RuvC motifs assemble to form the RuvC domain. The HNH domain shares structural similarity with HNH endonucleases and cleaves a single strand, e.g., the complementary strand, of a target nucleic acid molecule. The HNH domain is located between the RuvC II-III motifs and includes amino acids 775-908 of the S. pyogenes Cas9 sequence. The PI domain interacts with the PAM of the target nucleic acid molecule and includes amino acids 1099-1368 of the S. pyogenes Cas9 sequence.

[0119] Crystal structures have been determined for the naturally occurring bacterial Cas9 nuclease (see, e.g., Jinek et al., Science, 343(6176):1247997, 2014) and for Streptococcus pyogenes Cas9 with guide RNAs (e.g., synthetic fusions of crRNA and tracrRNA) (Nishimasu et al., Cell, 156:935-949, 2014, and Anders et al., Nature, 2014, doi:10.1038 / naturel3579).

[0120] In some embodiments, the Cas9 molecules described herein exhibit nuclease activity, resulting in the introduction of a double-stranded DNA break at or immediately proximal to the target site. In some embodiments, the Cas9 molecule is modified to inactivate one of the endonuclease's catalytic residues. In some embodiments, the Cas9 molecule is a nickase, generating a single-strand break. See, e.g., Dabrowska et al. Frontiers in Neuroscience (2018) 12(75). It has been shown that one or more mutations within the enzyme's RuvC and HNH catalytic domains can improve Cas9 efficiency. See, e.g., Sarai et al. Currently Pharma. Biotechnol. (2017) 18(13). In some embodiments, the Cas9 molecule is fused to a second domain, e.g., a domain that modifies DNA or chromatin, e.g., a deaminase or demethylase domain. In some such embodiments, the Cas9 molecule is modified to eliminate its endonuclease activity.

[0121] In some embodiments, the Cas nucleases or Cas / gRNA complexes described herein are administered with a template for homology-directed repair (HDR). In some embodiments, the Cas nucleases or Cas / gRNA complexes described herein are administered without an HDR template.

[0122] In some embodiments, Cas9 nucleases are used that are modified to enhance the specificity of the enzyme (e.g., to reduce off-target effects and maintain robust on-target cleavage). In some embodiments, the Cas9 molecule is an enhanced specificity Cas9 variant (e.g., eSPCas9). See, e.g., Slaymaker et al. Science (2016) 351(6268):84-88. In some embodiments, the Cas9 molecule is a high-fidelity Cas9 variant (e.g., SpCas9-HF1). See, e.g., Kleinstiver et al. Nature (2016) 529:490-495.

[0123] Various Cas nucleases are known in the art and are available from a variety of sources, and can be engineered / modified to modulate one or more activities or specificities of the enzyme. The PAM sequence preferences and specificities of suitable Cas nucleases, such as suitable Cas9 nucleases such as SpCas9 and SaCas9, are known in the art. In some embodiments, the Cas nuclease is engineered / modified to recognize one or more PAM sequences. In some embodiments, the Cas nuclease is engineered / modified to recognize one or more PAM sequences that are different from the PAM sequence that the Cas nuclease recognizes without engineering / modification. In some embodiments, the Cas nuclease is engineered / modified to reduce the off-target activity of the enzyme.

[0124] In some embodiments, Cas nucleases are used that are further modified to alter the specificity of their endonuclease activity (e.g., to reduce off-target cleavage, decrease endonuclease activity or duration within cells, increase homology-guided recombination, or reduce non-homologous end joining). See, e.g., Komor et al. Cell (2017) 168:20-36. In some embodiments, Cas nucleases are used that are modified to alter the PAM recognition or preference of the endonuclease. For example, while SpCas9 recognizes the PAM sequence NGG, some variants of SpCas9 containing one or more modifications (e.g., VQR SpCas9, EQR SpCas9, VRER SpCas9) can recognize variant PAM sequences, such as NGA, NGAG, and / or NGCG. For another example, while SaCas9 recognizes the PAM sequence NNGRRT, some SaCas9 variants containing one or more modifications (e.g., KKH SaCas9) can recognize the PAM sequence NNNRRT. In another example, FnCas9 recognizes the PAM sequence NNG, while FnCas9 variants containing one or more modifications (e.g., RHA FnCas9) can recognize the PAM sequence YG. In another example, a Cas12a nuclease containing substitution mutations S542R and K607R recognizes the PAM sequence TYCV. In another example, a Cpf1 endonuclease containing substitution mutations S542R, K607R, and N552R recognizes the PAM sequence TATV. See, e.g., Gao et al. Nat. Biotechnol. (2017) 35(8):789-792.

[0125] In some embodiments, base editors are used to generate genomic modifications that result in the loss of expression of lineage-specific cell surface antigens or the expression of variants of lineage-specific cell surface antigens that are not targeted by immunotherapy. Base editors typically comprise a catalytically inactive or partially inactive Cas nuclease fused to a functional domain, such as a deaminase domain. See, for example, Eid et al. Biochem. J. (2018) 475(11):1955-1964; Rees et al. Nature Reviews Genetics (2018) 19:770-788. In some embodiments, a catalytically inactive Cas nuclease is referred to as a "dead Cas" or "dCas." In some embodiments, the endonuclease comprises an adenine base editor (ABE), such as dCas fused to an ABE evolved from the RNA adenine deaminase TadA. In some embodiments, the endonuclease comprises dCas fused to a cytidine deaminase enzyme (e.g., APOBEC deaminase, pmCDA1, activation-induced cytidine deaminase (AID)). In some embodiments, the catalytically inactive Cas molecule has reduced activity, e.g., is a nickase.

[0126] Examples of suitable base editors include, but are not limited to, BE1, BE2, BE3, HF-BE3, BE4, BE4max, BE4-Gam, YE1-BE3, EE-BE3, YE2-BE3, YEE-CE3, VQR-BE3, VRER-BE3, SaBE3, SaBE4, SaBE4-Gam, Sa(KKH)-BE3, Target-AID, Target-AID-NG, xBE3, eA3A-BE3, BE-PLUS, TAM, CRISPR-X, ABE7.9, ABE7.10, ABE7.10*, xABE, ABESa, VQR-ABE, VRER-ABE, Sa(KKH)-ABE, and CRISPR-SKIP. Additional examples of base editors can be found, for example, in U.S. Publication No. 2018 / 0312825A1, U.S. Publication No. 2018 / 0312828A1, and PCT Publication No. WO2018 / 165629A1, which are incorporated by reference in their entireties.

[0127] Some aspects of the present disclosure provide guide RNAs that are suitable, for example, to target RNA-guided nucleases provided herein to suitable target sites within the genome of a cell to produce modifications in the genome of the cell that result in reduced expression of the lineage-specific cell surface antigen, loss of expression of the lineage-specific cell surface antigen, or expression of a variant form of the lineage-specific cell surface antigen that is not recognized by an immunotherapeutic agent that targets the lineage-specific cell surface antigen.

[0128] Some exemplary suitable Cas9 gRNA scaffold sequences are provided herein, and additional suitable gRNA scaffold sequences will be apparent to those skilled in the art based on this disclosure. Such additional suitable scaffold sequences include, but are not limited to, those described in Jinek, et al. Science (2012) 337(6096):816-821, Ran, et al. Nature Protocols (2013) 8:2281-2308, PCT Publication No. WO2014 / 093694, and PCT Publication No. WO2013 / 176772.

[0129] For example, the binding domain of naturally occurring SpCas9 gRNA typically contains two RNA molecules: a crRNA (partially) and a tracrRNA. Variants of SpCas9 gRNA have been engineered that contain only a single RNA molecule, including both the crRNA and tracrRNA sequences covalently linked to each other, e.g., via a tetraloop or via a click chemistry-type covalent bond, and are generally referred to as "single guide RNAs" or "sgRNAs." Because naturally occurring Cas12a guide RNAs contain a single RNA molecule, suitable gRNAs for use with other Cas nucleases, such as Cas12a nucleases, typically contain only a single RNA molecule. Therefore, suitable gRNAs, sometimes referred to herein as sgRNAs, can be unimolecular (having a single RNA molecule) or modular (containing more than one, typically two separate RNA molecules).

[0130] Suitable gRNAs for targeting target sites in lineage-specific cell surface antigens may comprise multiple domains. In some embodiments, for example, in some embodiments where Cas9 nuclease is used, the unimolecular sgRNA may comprise, from 5' to 3': a targeting domain corresponding to a target site sequence in a lineage-specific cell surface antigen-encoding gene; a first complementarity domain; and a binding domain; a second complementarity domain (complementary to the first complementarity domain); the proximal domain, and Optionally, a tail domain.

[0131] Each of these domains is now described in more detail.

[0132] The gRNAs provided herein typically contain a targeting domain that binds to a target site within the genome of a cell. The target site is typically a double-stranded DNA sequence containing a PAM sequence and a targeting domain on the same strand as and immediately adjacent to the PAM sequence. The targeting domain of a gRNA typically contains an RNA sequence that is similar to the sequence of the targeting domain, sometimes with one or more mismatches, but typically corresponds to the targeting domain sequence in that it contains RNA instead of a DNA sequence. Thus, the targeting domain of a gRNA base-pairs (with full or partial complementarity) with the sequence of the double-stranded target site that is complementary to the sequence of the targeting domain and, therefore, the strand that is complementary to the strand containing the PAM sequence. It will be understood that the targeting domain of a gRNA typically does not contain a PAM sequence. It will further be understood that the location of the PAM can be 5' or 3' of the targeting domain sequence, depending on the nuclease employed. For example, the PAM is typically 3' of the targeting domain sequence for Cas9 nucleases and 5' of the targeting domain sequence for Cas12a nucleases. For illustrations of the location of the PAM and the mechanism of gRNA binding to the target site, see, e.g., Figure 1 of Vanegas et al., Fungal Biol Biotechnol. 2019;6:6, which is incorporated herein by reference. For additional illustrations and explanations of the mechanism of gRNA targeting of RNA-guided nucleases to the target site, see Fu Y et al., Nat Biotechnol 2014 (doi:10.1038 / nbt.2808), and Sternberg SH et al., Nature 2014 (doi:10.1038 / naturel3011), both of which are incorporated herein by reference.

[0133] The targeting domain can comprise a nucleotide sequence corresponding to the sequence of the targeting domain, i.e., the DNA sequence immediately adjacent to the PAM sequence (e.g., 5' of the PAM sequence for Cas9 nuclease, or 3' of the PAM sequence for Cas12a nuclease). The targeting domain sequence typically comprises 17-30 nucleotides and can either correspond exactly to the targeting domain sequence (i.e., without any mismatched nucleotides) or contain one or more, but typically no more than four, mismatches. Because the targeting domain is part of an RNA molecule, the DNA targeting domain will contain deoxyribonucleotides, while the gRNA typically contains ribonucleotides.

[0134] An exemplary illustration of a Cas9 target site comprising a 22-nucleotide targeting domain and an NGG PAM sequence, and a gRNA comprising a targeting domain that corresponds perfectly to the targeting domain (and thus base-pairs with perfect complementarity to the DNA strand complementary to the strand comprising the targeting domain and PAM), is provided below. [Table 1]

[0135] An exemplary illustration of a Cas12a target site comprising a 22-nucleotide targeting domain and a TTN PAM sequence, and a gRNA comprising a targeting domain that corresponds perfectly to the targeting domain (and thus base-pairs with perfect complementarity to the DNA strand complementary to the strand comprising the targeting domain and PAM), is provided below. [Table 2]

[0136] In some embodiments, the Cas12a PAM sequence is 5'-TTTV-3'.

[0137] While not wishing to be bound by theory, it is believed that, at least in some embodiments, the length of the targeting domain and its complementarity with the target sequence contribute to the specificity of the interaction of the gRNA / Cas9 molecular complex with the target nucleic acid. In some embodiments, the targeting domain of a gRNA provided herein is 5-50 nucleotides in length. In some embodiments, the targeting domain is 15-25 nucleotides in length. In some embodiments, the targeting domain is 18-22 nucleotides in length. In some embodiments, the targeting domain is 19-21 nucleotides in length. In some embodiments, the targeting domain is 15 nucleotides in length. In some embodiments, the targeting domain is 16 nucleotides in length. In some embodiments, the targeting domain is 17 nucleotides in length. In some embodiments, the targeting domain is 18 nucleotides in length. In some embodiments, the targeting domain is 19 nucleotides in length. In some embodiments, the targeting domain is 20 nucleotides in length. In some embodiments, the targeting domain is 21 nucleotides in length. In some embodiments, the targeting domain is 22 nucleotides in length. In some embodiments, the targeting domain is 23 nucleotides in length. In some embodiments, the targeting domain is 24 nucleotides in length. In some embodiments, the targeting domain is 25 nucleotides in length. In some embodiments, the targeting domain completely corresponds to a targeting domain sequence provided herein or a portion thereof without mismatches. In some embodiments, the targeting domain of a gRNA provided herein contains one mismatch with respect to a targeting domain sequence provided herein. In some embodiments, the targeting domain contains two mismatches with respect to a targeting domain sequence. In some embodiments, the targeting domain contains three mismatches with respect to a targeting domain sequence.

[0138] In some embodiments, the targeting domain comprises a core domain and a secondary targeting domain, e.g., as described in PCT Publication No. WO2015 / 157070, which is incorporated by reference in its entirety. In some embodiments, the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the 3'-most 8 to 13 nucleotides of the targeting domain). In some embodiments, the secondary domain is positioned 5' to the core domain. In some embodiments, the core domain completely corresponds to the targeting domain sequence or a portion thereof. In other embodiments, the core domain may comprise one or more nucleotides that are mismatched to corresponding nucleotides in the targeting domain sequence.

[0139] In some embodiments, for example, a Cas9 gRNA is provided. In some embodiments, the gRNA comprises a first complementarity domain and a second complementarity domain, wherein the first complementarity domain is complementary to the second complementarity domain and has sufficient complementarity to the second complementarity domain to form a double-stranded region, at least in some embodiments, under at least some physiological conditions. In some embodiments, the first complementarity domain is 5 to 30 nucleotides in length. In some embodiments, the first complementarity domain comprises three subdomains, from 5' to 3': a 5' subdomain, a central subdomain, and a 3' subdomain. In some embodiments, the 5' subdomain is 4 to 9 nucleotides in length, e.g., 4, 5, 6, 7, 8, or 9 nucleotides in length. In some embodiments, the central subdomain is 1, 2, or 3 nucleotides in length, e.g., 1 nucleotide. In some embodiments, the 3' subdomain is 3 to 25 nucleotides in length, e.g., 4 to 22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. The first complementarity domain can share homology with or be derived from a naturally occurring first complementarity domain. In one embodiment, it has at least 50% homology with a first complementarity domain of Streptococcus pyogenes, Staphylococcus aureus, or S. thermophilus.

[0140] The sequences and arrangements of the above-mentioned domains are described in more detail in PCT Publication No. WO2015 / 157070, which is incorporated by reference herein in its entirety, including pages 88-112 therein.

[0141] The binding domain may serve to link the first complementary domain to the second complementary domain of the unimolecular gRNA. The binding domain can link the first and second complementary domains covalently or non-covalently. In some embodiments, the linkage is a covalent bond. In some embodiments, the binding domain is or includes a covalent bond interposed between the first complementary domain and the second complementary domain. In some embodiments, the binding domain comprises one or more nucleotides, for example, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the binding domain comprises at least one non-nucleotide linkage, for example, as disclosed in PCT Publication No. WO2018 / 126176, the entire contents of which are incorporated herein by reference.

[0142] In some embodiments, the second complementarity domain is at least partially complementary to the first complementarity domain, and in one embodiment, has sufficient complementarity to the second complementarity domain to form a double-stranded region under at least some physiological conditions. In some embodiments, the second complementarity domain can include a sequence that lacks complementarity with the first complementarity domain, e.g., a sequence that creates a loop from the double-stranded region. In some embodiments, the second complementarity domain is 5 to 27 nucleotides in length. In some embodiments, the second complementarity domain is longer than the first complementarity domain. In one embodiment, the complementarity domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 nucleotides in length. In some embodiments, the second complementarity domain comprises three subdomains, from 5' to 3': a 5' subdomain, a central subdomain, and a 3' subdomain. In some embodiments, the 5' subdomain is 3 to 25 nucleotides in length, e.g., 4 to 22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 nucleotides in length. In some embodiments, the central subdomain is 1, 2, 3, 4, or 5 nucleotides in length, e.g., 3 nucleotides in length. In some embodiments, the 3' subdomain is 4 to 9 nucleotides in length, e.g., 4, 5, 6, 7, 8, or 9 nucleotides in length. In some embodiments, the 5' and 3' subdomains of the first complementarity domain are complementary, eg, perfectly complementary, to the 3' and 5' subdomains of the second complementarity domain, respectively.

[0143] In some embodiments, the proximal domain is 5-20 nucleotides in length. In some embodiments, the proximal domain shares homology with or can be derived from a naturally occurring proximal domain. In one embodiment, it has at least 50% homology with a proximal domain from Streptococcus pyogenes, Staphylococcus aureus, or Streptococcus thermophilus.

[0144] A wide range of tail domains are suitable for use in gRNAs. In some embodiments, the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In some embodiments, the tail domain nucleotides are derived from or share homology with sequences from the 5' end of a naturally occurring tail domain. In some embodiments, the tail domains comprise sequences that are complementary to each other and form a double-stranded region under at least some physiological conditions. In some embodiments, the tail domain is absent or is 1-50 nucleotides in length. In some embodiments, the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In some embodiments, the tail domain has at least 50% homology / identity to a tail domain from Streptococcus pyogenes, Staphylococcus aureus, or Streptococcus thermophilus. In some embodiments, the tail domain includes nucleotides at the 3' end that are relevant for in vitro or in vivo transcription methods.

[0145] In some embodiments, the gRNAs provided herein are For example, in the 5' to 3' direction, a targeting domain (corresponding to the targeting domain in the CD30 gene), and a first strand comprising a first complementarity domain; For example, in the 5' to 3' direction, optionally, a 5' extension domain; a second complementarity domain, the proximal domain, and and optionally a second strand comprising a tail domain.

[0146] In some embodiments, any of the gRNAs provided herein contain one or more chemically modified nucleotides. Chemical modifications of gRNAs have been previously described, and suitable chemical modifications include any modifications that are beneficial to gRNA function and do not measurably increase any undesirable properties of a given gRNA, such as off-target effects. Suitable chemical modifications include, for example, those that render the gRNA less susceptible to endonuclease or exonuclease catalytic activity, including, but not limited to, phosphorothioate backbone modifications, 2'-O-Me modifications (e.g., at one or both of the 3' and 5' ends), 2'F modifications, replacement of the ribose sugar with the bicyclic nucleotide-cEt, 3' thioPACE (MSP) modifications, or any combination thereof. Additional suitable gRNA modifications will be apparent to those of skill in the art based on the present disclosure, and include, but are not limited to, those described in, for example, Rahdar et al. PNAS (2015) 112(51) E7110-E7117, and Hendel et al., Nat Biotechnol. (2015); 33(9): 985-989, each of which is incorporated herein by reference in its entirety.

[0147] For example, gRNAs provided herein can contain one or more 2'-O-modified nucleotides, e.g., 2'-O-methyl nucleotides. In some embodiments, gRNAs contain 2'-O-modified nucleotides, e.g., 2'-O-methyl nucleotides, at the 5' end of the gRNA. In some embodiments, gRNAs contain 2'-O-modified nucleotides, e.g., 2'-O-methyl nucleotides, at the 3' end of the gRNA. In some embodiments, gRNAs contain 2'-O-modified nucleotides, e.g., 2'-O-methyl nucleotides, at both the 5' and 3' ends of the gRNA. In some embodiments, gRNAs are 2'-O-modified, e.g., at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified, e.g., the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA are 2'-O-methyl modified. In some embodiments, the gRNA is 2'-O modified, e.g., the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA are 2'-O-methyl modified. In some embodiments, the gRNA is 2'-O modified, e.g., the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA are 2'-O-methyl modified. In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified. In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar.In some embodiments, the gRNA is 2'-O-modified, for example, at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA. In some embodiments, the 2'-O-methyl nucleotide comprises a phosphate linkage to the adjacent nucleotide. In some embodiments, the 2'-O-methyl nucleotide comprises a phosphorothioate linkage to the adjacent nucleotide. In some embodiments, the 2'-O-methyl nucleotide comprises a thioPACE linkage to the adjacent nucleotide.

[0148] In some embodiments, the gRNAs provided herein may contain one or more 2'-O-modified and 3'-phosphorus modified nucleotides, such as 2'-O-methyl 3' phosphorothioate nucleotides. In some embodiments, the gRNAs contain 2'-O-modified and 3'-phosphorus modified nucleotides, such as 2'-O-methyl 3' phosphorothioate nucleotides, at the 5' end of the gRNA. In some embodiments, the gRNAs contain 2'-O-modified and 3'-phosphorus modified nucleotides, such as 2'-O-methyl 3' phosphorothioate nucleotides, at the 3' end of the gRNA. In some embodiments, the gRNAs contain 2'-O-modified and 3'-phosphorus modified nucleotides, such as 2'-O-methyl 3' phosphorothioate nucleotides, at the 5' and 3' ends of the gRNA. In some embodiments, the gRNAs contain a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' phosphorothioate modified at the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified. In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar. In some embodiments, the gRNA is 2'-O-modified and 3' phosphorus-modified, for example, 2'-O-methyl 3' phosphorothioate-modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.

[0149] In some embodiments, the gRNAs provided herein may comprise one or more 2'-O and 3'-phosphorus modifications, such as 2'-O-methyl 3'-thio PACE nucleotides. In some embodiments, the gRNAs comprise a 2'-O and 3'-phosphorus modification, such as 2'-O-methyl 3'-thio PACE nucleotides, at the 5' end of the gRNA. In some embodiments, the gRNAs comprise a 2'-O and 3'-phosphorus modification, such as 2'-O-methyl 3'-thio PACE nucleotides, at the 3' end of the gRNA. In some embodiments, the gRNAs comprise a 2'-O and 3'-phosphorus modification, such as 2'-O-methyl 3'-thio PACE nucleotides, at the 5' and 3' ends of the gRNA. In some embodiments, the gRNAs comprise a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom and one or more non-bridging oxygen atoms are replaced with an acetate group. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' thio PACE modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' thio PACE modified at the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' thio PACE modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' thio PACE modified at the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified. In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar. In some embodiments, the gRNA is 2'-O-modified and 3' phosphorus-modified, for example, 2'-O-methyl 3' thio PACE-modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.

[0150] In some embodiments, the gRNAs provided herein comprise a chemically modified backbone. In some embodiments, the gRNA comprises a phosphorothioate bond. In some embodiments, one or more non-bridging oxygen atoms are replaced with a sulfur atom. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a phosphorothioate linkage. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a phosphorothioate linkage.

[0151] In some embodiments, the gRNAs provided herein comprise a thioPACE bond. In some embodiments, the gRNA comprises a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom and one or more non-bridging oxygen atoms are replaced with an acetate group. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA each comprise a thioPACE bond. In some embodiments, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a thioPACE bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a thioPACE bond. In some embodiments, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a ThioPACE bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a ThioPACE bond.

[0152] In some embodiments, the gRNAs described herein comprise one or more 2'-O-methyl-3'-phosphorothioate nucleotides, e.g., at least 1, 2, 3, 4, 5, or 6 2'-O-methyl-3'-phosphorothioate nucleotides. In some embodiments, the gRNAs described herein comprise modified nucleotides (e.g., 2'-O-methyl-3'-phosphorothioate nucleotides) at one or more of the three terminal positions and the 5' end, and / or at one or more of the three terminal positions and the 3' end. In some embodiments, the gRNAs may comprise one or more modified nucleotides, e.g., as described in PCT Publication Nos. WO2017 / 214460, WO2016 / 089433, and WO2016 / 164356, which are incorporated by reference in their entireties.

[0153] How to use Some aspects of the present disclosure provide methods comprising administering a plurality of the cells provided herein to a subject in need thereof. For example, some aspects of the present disclosure provide methods comprising administering a plurality, preferably an effective number, of the cells provided herein, e.g., engineered cells (the cells are recruited lymphocyte cells) comprising a heterologous nucleic acid encoding a transgene (e.g., a CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative / neoplastic / malignant disease, to a subject in need thereof. In some embodiments, the engineered lymphocytes expressing the CAR are T lymphocytes. In some embodiments, the engineered lymphocytes expressing the CAR are B lymphocytes. In some embodiments, the engineered lymphocytes expressing the CAR are NK cells.

[0154] In some embodiments, the subject also receives a plurality, and preferably an effective number, of genetically engineered hematopoietic stem cells, wherein the genetically engineered hematopoietic stem cells are characterized by reduced or absent expression of a lineage-specific cell surface antigen, or expression of a variant form of the lineage-specific cell surface antigen that is not recognized by the CAR or is recognized at a reduced level. In some embodiments, the cells are HSCs or HPCs.

[0155] In some embodiments, the method further comprises monitoring at least one symptom of the hyperproliferative disease.

[0156] Some aspects of the present disclosure provide a method for administering the cells provided herein, for example, genetically engineered lymphocytes expressing a CAR that targets a lineage-specific cell surface antigen, to a subject with a hyperproliferative disease, for example, a hematopoietic malignancy, such as a myeloid malignancy or lymphoid malignancy. In some embodiments, the subject has or has been diagnosed with a hyperproliferative disease. In some embodiments, the subject has or has been diagnosed with a hyperproliferative disease, but the disease has not yet progressed to a malignant state, such as a pre-malignant stage of the disease.

[0157] In some embodiments, administration of the cells to a subject ameliorates signs or symptoms associated with a hyperproliferative disease, which may include, for example, reducing the number of neoplastic or malignant cells, reducing tumor burden, including inhibiting tumor growth, slowing the rate of tumor growth, reducing tumor size, reducing the number of tumors, eliminating tumors, or reducing or ameliorating symptoms associated with a neoplastic disease or disorder, such as fatigue, pain, weight loss, and other clinical measures.

[0158] In some embodiments, the subject is a mammal, hi some embodiments, the subject is a human subject.

[0159] In some embodiments, the subject has or has been diagnosed with a hyperproliferative disease. In some embodiments, the hyperproliferative disease is a hematopoietic malignancy. In some embodiments, the hematopoietic malignancy is a myeloid malignancy. In some embodiments, the hematopoietic malignancy is a lymphoid malignancy. In some embodiments, the hematopoietic malignancy is Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma. In some embodiments, the leukemia is acute myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, or chronic lymphoblastic leukemia, or chronic lymphocytic leukemia. In some embodiments, the cancer is acute myeloid leukemia (AML). In some embodiments, the neoplastic disease is myelodysplastic syndrome.

[0160] In some embodiments, the hyperproliferative disease is a sarcoma. In some embodiments, the hyperproliferative disease is a melanoma. In some embodiments, the hyperproliferative disease is a brain or spinal cord tumor. In some embodiments, the hyperproliferative disease is a germ cell tumor. In some embodiments, the hyperproliferative disease is a neuroendocrine tumor. In some embodiments, the hyperproliferative disease is a carcinoid tumor. In some embodiments, the hyperproliferative disease is a hematopoietic cancer. In some embodiments, the hyperproliferative disease is a metastatic cancer.

[0161] Depending on the CAR employed in the cells provided herein, various diseases or malignancies may be treated, including, but not limited to, bone cancer, intestinal cancer, liver cancer, skin cancer, head and neck cancer, melanoma (cutaneous or intraocular malignant melanoma), kidney cancer (e.g., clear cell carcinoma), pharyngeal cancer, prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), blood cancer (e.g., leukemia, lymphoma, and myeloma), uterine cancer, rectal cancer, anal cancer, bladder cancer, brain cancer, stomach cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, and the like. cervix), vaginal cancer, vulvar cancer, leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease, Waldenstrom's macroglobulinemia, erythrocyte sedimentation, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumors, lymphocytic lymphoma, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal axis tumors, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma solid tumors such as sarcomas and carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial tumor, lymphangiosarcoma, lymphangioendothelial tumor, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, bladder cancerSolid tumors include epithelial cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, retinoblastoma, malignant pleural disease, mesothelioma, lung cancer (e.g., non-small cell lung cancer), pancreatic cancer, ovarian cancer, breast cancer (e.g., metastatic breast cancer, metastatic triple-negative breast cancer), colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, and synovial sarcoma. Solid tumors can be primary tumors or tumors in a metastatic state.

[0162] In some embodiments, the genetically engineered cells provided herein, e.g., genetically engineered lymphocytes, genetically engineered hematopoietic stem cells that express a CAR, are administered in amounts that are approximately 10% of the subject's body weight. 4 ~about 10 10 cells / kg, e.g., about 10 5 ~about 10 9 , about 10 5 ~about 10 8 , about 10 5 ~about 10 7 , or about 10 5 ~10 6 The cell is administered to a subject in need thereof at a dose of 1000 mg / kg / day. Generally, a higher dose is used for systemic administration than for local administration. The dose of any of the cells described herein may also be adjusted to take into account whether a single dose or multiple doses are administered. The exact determination of what is considered an effective dose can be based on individual factors for each subject, including the size, age, sex, weight, and condition of the specific subject, as described above. The dosage can be easily determined by those skilled in the art based on the disclosure herein and knowledge in the art.

[0163] The genetically engineered cells provided herein may be administered by any method known in the art, including, but not limited to, intrapleural administration, intravenous administration, subcutaneous administration, intranodal administration, intratumoral administration, intrathecal administration, intrapleural administration, intraperitoneal administration, intracranial administration, and direct administration into the thymus. [Example]

[0164] Example 1: As shown in the exemplary schematics shown in Figures 1 and 2, edited hematopoietic stem cells and cells engineered to express a chimeric antigen receptor (CAR) may be produced from a single starting material.

[0165] Briefly, a donor (e.g., a healthy, HLA-matched donor) is administered a mobilization agent, such as any of those described herein, that promotes mobilization of cells typically located in the subject's bone marrow. An apheresis product is obtained from the donor subject containing a heterogeneous population of mobilized cells, including hematopoietic stem cells and PMBCs. CD34+ cells (HSCs, which may be referred to as "target cells") are isolated from the starting material and used to produce an edited hematopoietic stem cell (eHSC) drug product. For example, hematopoietic stem cells may be CD33 (CD34+ / CD33 neg They may be genetically engineered to have reduced or no expression of lineage-specific cell surface antigens, such as eHSCs.

[0166] The remaining cell population (referred to as the "non-target fraction"), which may typically be discarded, is genetically engineered by transduction with a heterologous nucleic acid encoding a CAR to produce a CAR drug product, e.g., CAR-T cells. The CAR drug product cells can be stored for later administration to the patient after eHSC engraftment.

[0167] Example 2: G-CSF / Plerixafor Dual-Mobilized Donor-Derived CD33 CAR-T Cells as a Potent and Effective AML Therapy in Preclinical Models Currently, there are no acute myeloid leukemia (AML)-specific antigens. Genetic ablation of CD33 using CRISPR / Cas9 manipulation of hematopoietic stem cells (HSCs) for transplantation represents a synthetic biology approach to generating leukemia-specific antigens in transplant recipients. Transplantation of CD33KO HSCs allows CD33-targeted immunotherapy (e.g., mediated by anti-CD33 CAR-T cells) to kill AML cells while sparing the edited CD33KO HSCs, thus maintaining the continuation of myeloid development and function maintained by these CD33KO HSCs, thereby mitigating the on-target, off-cancer toxicities of CD33-targeted immunotherapy.

[0168] Mobilized leukapheresis is used to generate CD33-edited (CD33) null (CD33) T cells for transplantation. - (CD33KO or CD33KO) HSCs represent an attractive starting material for generating both complementary immunotherapeutic agents, such as CD33 CAR-T cell products. The impact of dual mobilization with granulocyte colony-stimulating factor (G-CSF) and plerixafor (Mozobil) on immune cell composition, T cell phenotype, and the functionality of these T cells to control AML tumor growth upon chimeric antigen receptor (CAR) transduction is described below.

[0169] Mobilized ("mob") PBMCs were collected from healthy donors injected with G-CSF (10 μg / kg / day for 5 consecutive days) and plerixafor (240 μg / kg on days 4 and 5). Non-mobilized ("non-mob," sometimes referred to herein and in figures as "steady-state," or "ss") PBMCs collected from the same donors served as controls. Cells were analyzed by flow cytometry for immunophenotyping and T cell characteristics, including differentiation and bone marrow homing markers, and response to T cell activation with anti-CD3 (OKT3) and IL-2.

[0170] To assess the cell types comprising the mobilized cell population, we performed a global immunophenotyping analysis using flow cytometry. The mobilized cell population was found to contain populations of T cells, monocytes, NK cells, and B cells. See Figures 3A-3D. As shown in Figure 3E, the relative abundance of specific cell types present in the mobilized cell population differed from that in the steady-state cell population. For example, the relative abundance of CD3+ cells (T cells) decreased in the mobilized cell population compared to the steady-state, whereas the relative abundance of B cells increased in the mobilized cell population compared to the steady-state.

[0171] The phenotype of T cells in the mobilized cell population was further evaluated. As shown in Figures 3F-3H, naive, effector, and memory T cells were present in the mobilized cell population, but the relative abundance of naive T cells increased in the mobilized cell population compared to the steady state. Furthermore, the relative abundance of effector and memory T cells decreased in the mobilized cell population compared to the steady state.

[0172] The immune and T cell phenotypic analyses described above were performed on non-mobilized and mobilized PBMC populations from multiple donors. See Figures 4A-4C. As shown in Figure 4D, distinct T cell subsets (CD8 + or CD4 + ) were also analyzed. Ex vivo immunophenotyping of PBMCs from a total of 30 healthy donors revealed that mobilization was dominated by CD3 + It reduces the total number of T cells but also increases T effector memory (CD45RA - / CCR7 - ) and Central Memory (CD45RA - / CCR7 + ) population and naive T cells (CD45RA + / CCR7 + ) was shown to increase the number of

[0173] Non-mobilized and mobilized PBMC populations were also analyzed by single-cell next-generation sequencing (CITEseq) using 127 immune cell phenotypic markers combined with extensive transcriptome and T cell receptor repertoire analysis. CITEseq results for two donors (D1 and D2) are shown in Figure 5 (PBMC population analysis) and Figure 6 (T cell subset analysis). Single-cell sequencing analysis revealed a mobilization-induced increase in naive T cells, as well as monocytes / macrophages, CD4 + A shift in the proportion of T cells and NK cells was observed.

[0174] Additionally, bone marrow homing factors (e.g., sialyl Lewis X , CXCR4) was observed to be somewhat decreased in mobilized compared to non-mobilized T cell samples.

[0175] T cell activation (using standard anti-CD3 and IL-2 protocols) resulted in similar increases in CD25, CD69, and CD137 expression, and decreases in CD62L expression across non-mobilized and mobilized PBMC populations. Figure 7 shows the changes in protein expression for non-mobilized and mobilized PBMC populations obtained from two donors (D1 and D2), and Figure 8 shows activation-induced changes in marker expression for the larger donor cohort. Monocytes (CD14 + ) were higher compared to non-mobilized donor samples, but disappeared after culture under T cell-activating conditions.

[0176] Lentiviral transduction of anti-CD33 CAR constructs allowed functional comparison of mob-CAR and non-mob-CAR T cells in AML cell cocultures and AML mouse models.

[0177] Lentiviral constructs encoding anti-CD33 CARs containing the M195 (anti-CD33) binder, CD28 hinge and transmembrane domains, and CD3 zeta signaling domains, as well as CAR-T cells, were obtained from mobilized and non-mobilized PBMC fractions by standard lentiviral transduction protocols (see, for example, PCT / US2020 / 022309 for reference). The sequence of the CAR is as follows:

[0178] MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPY NGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSSGGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGT DFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIKSGAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPL FPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIG MKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGS (SEQ ID NO: 1)

[0179] Mob-CD33-CAR T cells express CD33, accompanied by a reduction in "bystander" activation of non-transduced T cells. +Functional in vitro cytotoxicity assays demonstrated that CAR T cells were as effective as non-mob-CD33-CAR T cells in killing AML cells (Figures 9-11). Non-mobilized PBMC populations yielded a CAR expression frequency of approximately 28%, while mobilized PBMC populations yielded approximately 27% CAR-expressing cells. Target cells included CD33-expressing MOLM13 cells (wt MOLM), CD33-null MOLM13 cells (CD33KO MOLM), and Jurkat cells (no CD33 expression). CAR-T cells and target cells were co-cultured for 24 hours. Control conditions included cells without stimulation (negative control) and cells with standard PMA / ionomycin stimulation (PMA / I, positive control). In some cases, MYLOTARG (商標) was used as an additional positive control. Assays were performed at least in duplicate.

[0180] Figure 9 shows that the cytotoxic potential of mobilized PBMC-derived CAR-T cells is equivalent to that of non-mobilized PBMC-derived CAR-T cells.

[0181] Figure 10 shows that intracellular activation markers are upregulated in a similar manner in mobilized and non-mobilized PBMC-derived CAR-T cells with minimal "bystander" activation, and that both CD8+ and CD8- T cells are activated to produce IFNγ and TNFα in a CAR- and antigen-dependent manner.

[0182] Figure 11 shows LUMINEX of supernatant cytokines. (商標) The analysis is presented and confirms the results of comparable cytotoxic potential of non-mobilized and mobilized PBMC-derived CAR-T cells.

[0183] Evaluation of the cytotoxic potential of non-mobilized and mobilized PBMC-derived CAR-T cells in an in vivo AML mouse model is shown in Figure 12, where mobilized CD33-CAR T cells exhibited comparable cytotoxic potential to non-mobilized CD33-CAR T cells, demonstrating a CD33 + It has been shown to be effective in removing tumors.

[0184] The data presented herein demonstrate ex vivo phenotypic differences between mob and non-mob PBMCs, which largely disappear upon activation and display similar responses to T cell-specific stimuli. These findings are supported by the similar in vitro cytotoxicity profiles of non- / mob-CAR T cells. Untransduced T cells in the mob-CAR T cell population exhibited limited "bystander" activation and a potentially favorable clinical toxicity profile. Additional in vivo evaluation of mob-CAR T cell function demonstrated effective tumor clearance, supporting further efforts toward their clinical use in combination with engineered HSCs for the treatment of AML patients.

[0185] References All publications, patents, patent applications, publications, and database entries (e.g., sequence database entries) mentioned herein, for example in the Background, Summary, Detailed Description, Examples, and / or References sections, are incorporated herein by reference in their entirety, just as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In case of conflict, the present application, including any definitions herein, will control.

[0186] Equivalents and Scope Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.

[0187] Articles such as "a," "an," and "the" can mean one or more than one unless indicated to the contrary or clear from context. A claim or specification including "or" between two or more members of a group is deemed to be satisfied when one, more than one, or all of the group members are present, unless indicated to the contrary or clear from context. The disclosure of a group including "or" between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one member of the group is present, and embodiments in which all of the group members are present. For brevity, these embodiments are not individually detailed herein, but it will be understood that each of these embodiments is provided herein and can be specifically claimed or denied.

[0188] It should be understood that the present invention encompasses all variations, combinations, and permutations of one or more limitations, elements, clauses, or descriptive terms from one or more of the claims, or from one or more relevant portions of the specification, introduced into another claim. For example, a claim that relies on another claim can be modified to include one or more of the limitations found in any other claim that relies on the same base claim. Furthermore, if a claim recites a composition, it should be understood that it includes methods of making or using the composition according to any of the methods of making or using disclosed herein, or according to methods known in the art, if any, unless otherwise indicated or unless a contradiction or inconsistency would arise.

[0189] When elements are presented as a list, for example, in Markush group format, it is understood that all possible subgroups of the elements are also disclosed, and that any element or subgroup of elements can be deleted from the group. It should also be noted that the term "comprising" is intended to be open-ended, allowing for the inclusion of additional elements or steps. In general, when an embodiment, product, or method is referred to as comprising a particular element, feature, or step, it should be understood that an embodiment, product, or method consisting of or consisting essentially of such element, feature, or step is also provided. For purposes of brevity, these embodiments are not individually detailed herein, but it will be understood that each of these embodiments can be provided herein and specifically claimed or denied.

[0190] When ranges are given, the endpoints are included. Furthermore, unless otherwise indicated or apparent from the context and / or the understanding of one of ordinary skill in the art, it should be understood that values ​​expressed as ranges can, in some embodiments, assume any specific value within the stated range, down to 1 / 10 of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For brevity, each range value is not individually detailed herein, but it should be understood that each of these values ​​is provided herein and can be specifically claimed or disclaimed. It should also be understood that, unless otherwise indicated or apparent from the context and / or the understanding of one of ordinary skill in the art, values ​​expressed as ranges can assume any subrange within the given range, with the endpoints of the subranges being expressed to the same degree of precision as 1 / 10 of the unit of the lower limit of the range.

[0191] In addition, it should be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where a range is given, any value within that range may be explicitly excluded from any one or more of the claims. Any embodiment, element, feature, use, or aspect of the compositions and / or methods described herein may be excluded from any one or more of the claims. For the sake of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects are excluded are not explicitly set forth herein.

Claims

1. 1. A genetically engineered cell comprising: a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease; The genetically engineered cells, wherein the cells are mobilized lymphoid cells, or progeny thereof, obtained from the subject following hematopoietic stem cell mobilization including etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony stimulating factor (G-CSF).

2. the genetically engineered cell is a T lymphocyte, a B lymphocyte, or a natural killer (NK) cell; Wherein, when the genetically engineered cell is a T lymphocyte, optionally, the T lymphocyte comprises: (i) expresses CD3, CD4, and / or CD8; (ii) expresses PD1; (iii) are alpha / beta T lymphocytes or gamma / delta T lymphocytes; and / or (iv) a naive T lymphocyte, an effector T lymphocyte, a memory T lymphocyte, or a regulatory T lymphocyte (Treg); The genetically engineered cell of claim 1.

3. 3. The genetically engineered cell of claim 1 or 2, wherein the chimeric antigen receptor is a first generation CAR, a second generation CAR, or a third generation CAR.

4. 4. The genetically engineered cell of any one of claims 1 to 3, wherein the lineage-specific cell surface antigen is CD33, CD30, CD38, CD123, CLL-1, CD5, CD6, CD7, CD19, or BCMA.

5. The hyperproliferative disease is a hematopoietic malignancy, optionally wherein the hematopoietic malignancy is (i) a myeloid or lymphoid malignancy; (ii) Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma; and / or (iii) acute myeloid leukemia or myelodysplastic syndrome, A genetically engineered cell according to any one of claims 1 to 4.

6. 1. A method comprising: contacting mobilized lymphocytes obtained from the first subject with a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) that targets a lineage-specific cell surface antigen associated with a hyperproliferative disease, thereby producing engineered lymphocytes that express said CAR, wherein mobilization is hematopoietic stem cell mobilization comprising administering to the first subject etoposide, plerixafor, cyclophosphamide, and / or granulocyte colony-stimulating factor (G-CSF); The method.

7. 7. The method of claim 6, contacting hematopoietic stem cells obtained from the first subject with an RNA-guided nuclease and a guide RNA, or a nucleic acid encoding an RNA-guided nuclease and a guide RNA, wherein the guide RNA targets a gene encoding the lineage-specific cell surface antigen; thereby producing genetically engineered hematopoietic stem cells that have reduced or absent expression of said lineage-specific cell surface antigen, or express a variant form of said lineage-specific cell surface antigen, wherein the genetically engineered hematopoietic stem cells are not targeted by the CAR.

8. The recruited lymphocytes are T lymphocytes, B lymphocytes, or natural killer (NK) cells; Wherein, when the genetically engineered cell is a T lymphocyte, optionally, the T lymphocyte comprises: (i) expresses CD3, CD4, and / or CD8; (ii) expresses PD1; (iii) are alpha / beta T lymphocytes or gamma / delta T lymphocytes; and / or (iv) a naive T lymphocyte, an effector T lymphocyte, a memory T lymphocyte, or a regulatory T lymphocyte (Treg); The method according to claim 6 or 7.

9. The method of any one of claims 6 to 8, wherein the chimeric antigen receptor is a first generation CAR, a second generation CAR, or a third generation CAR.

10. 10. The method of any one of claims 6 to 9, wherein the lineage-specific cell surface antigen is CD33, CD30, CD38, CD123, CLL-1, CD5, CD6, CD7, CD19, or BCMA.

11. The hyperproliferative disease is a hematopoietic malignancy, and optionally, the hematopoietic malignancy is (i) a myeloid or lymphoid malignancy; (ii) Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma; and / or (iii) acute myeloid leukemia or myelodysplastic syndrome, The method according to any one of claims 6 to 10.

12. (i) the RNA-guided nuclease is a CRISPR / Cas nuclease, optionally wherein the CRISPR / Cas nuclease is a Cas9 nuclease, a SpCas nuclease, a SaCas nuclease, or a Cpf1 nuclease; (ii) the nucleic acid encoding the guide RNA and / or the RNA-guided nuclease is RNA, preferably an mRNA or an mRNA analogue; and / or (iii) the guide RNA comprises one or more nucleotide residues that are chemically modified, one or more nucleotide residues that contain a 2'O-methyl moiety, one or more nucleotide residues that contain a phosphorothioate, and / or one or more nucleotide residues that contain a ThioPACE moiety; The method according to any one of claims 8 to 11.

13. 13. A cell population comprising a plurality of genetically engineered lymphocytes expressing a CAR produced, obtained, or obtainable by a plurality of genetically engineered cells of any one of claims 1 to 5, or a method of any one of claims 6 to 12.

14. 14. The cell population of claim 13 for use in a method comprising administering said cell population to a second subject in need thereof, optionally wherein the second subject is (a) having or being diagnosed with a hyperproliferative disease, and / or (b) is different from the first object or is the same as the first object; The cell population.

15. A cell population for use according to claim 14, comprising: (i) the second subject has undergone a hematopoietic stem cell transplant comprising genetically engineered stem cells that have reduced or absent expression of a lineage-specific cell surface antigen, or express a variant form of said lineage-specific cell surface antigen that is not recognized or is recognized at a reduced level by said CAR; (ii) the method of administering the cell population to a second subject further comprises, after administration of the engineered lymphocytes or progeny thereof, administering a hematopoietic stem cell transplant to the second subject, wherein said transplant comprises engineered hematopoietic stem cells that have reduced or no expression of said lineage-specific cell surface antigen, or express a variant form of said lineage-specific cell surface antigen that is not recognized or is recognized at a reduced level by said CAR; or (iii) the method of administering the cell population to a second subject comprises administering the engineered lymphocytes or progeny thereof in combination with a hematopoietic stem cell transplant comprising engineered hematopoietic stem cells that have reduced or absent expression of the lineage-specific cell surface antigen, or express a variant form of the lineage-specific cell surface antigen that is not recognized or is recognized at a reduced level by the CAR; The cell population.